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ABSTRACT 
 Passive antibody treatments are used to target infectious disease, toxins, venoms, 
and cancer antigens.  Recently, there has been an increased interest in the use of avian-
derived antibody treatments such as IgY.  IgY is the primary serum antibody isotype 
present in the avian system, and IgY treatments have already been demonstrated to be 
effective against a variety of bacterial and viral infectious agents.  There are two forms of 
IgY expressed in anseriformes birds, a full length IgY that is functionally similar to 
mammalian IgG, and an alternatively spliced IgY, IgY(ΔFc), that is comparable to the 
mammalian F(ab’)2 fragment.  The difference in structure between IgY and mammalian 
IgG, prevents IgY from interacting with mammalian Fc receptors, complement, and other 
inflammatory factors.  The phylogenetic distance between mammalian and avian species 
allows IgY to have a higher avidity for certain mammalian epitopes and a unique 
antibody repertoire is developed compared to mammals, further enhancing the 
therapeutic potential of IgY.   
 Our current research is focused on developing goose IgY anti-viral treatments and 
ensuring the safety of these treatments in humans.  The viral antigens of focus in this 
research are dengue virus type 2 (DENV-2) and the Andes virus (ANDV).  In an attempt 
to generate monoclonal goose IgY antibodies, using modified mammalian hybridoma 
techniques, geese were immunized with DENV-2 antigen and blood was collected as a 
source of immune B-cells and fused with mammalian myeloma cells.  Short lasting, 
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virus- specific IgY producing hyrbidomas were created.  To generate ANDV specific 
goose IgY antibodies geese were vaccinated with a DNA vaccine PWRG/AND-M, 
containing the full-length M genome segment of ANDV, via a needle-free device at two 
week intervals up to eight weeks and then at 12 weeks.  One year later the same geese 
were booster vaccinated with either pWRG/AND(opt) or pWRG/AND(opt2) six times 
over a ten week time period.  Average neutralizing titers of sera collected from geese six 
weeks after the primary vaccination was 10,000.  Titers remained at this level for the one 
year in between vaccinations and then increased to nearly 100,000 after booster 
vaccination.  Epitope mapping confirmed the specificity of the goose- derived antibodies 
and identified unique highly reactive epitopes.  IgY from the initial vaccination 
recognized 11 epitopes across the M segment, and an additional 9 epitopes after booster 
vaccination.  In vivo survival studies in a lethal challenge model of ANDV infection 
established the post-exposure treatment potential of the ANDV specific IgY.  
To test the safety of the anti-viral IgY treatments for use in humans in vivo and in 
vitro safety experiments were completed.  In a single injection study, mice were injected 
with a single dose of IgY/IgY(ΔFc) or PBS, and in a multiple injection study, rabbits 
were injected with multiple doses of IgY/IgY(ΔFc), IgY(ΔFc), human immunoglobulin, 
or PBS.  Organs were collected after injection, hematoxylin and eosin stained, and scored 
by a blinded pathologist for abnormal pathology and/or inflammation.  There were no 
inflammatory manifestations in the organs from animals in either the single or multiple 
injection study receiving IgY/IgY(ΔFc) or IgY(ΔFc).  PBMCs and neutrophils were 
isolated from fresh human blood and co-cultured with IgY/IgY(ΔFc), mammalian IgG, 
and other controls.  Culture supernatants were collected at various time points and 
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analyzed for the presence of IL-1β, TNF-α, IL-10, neutrophil elastase, and nitric oxide 
using kit-based assays.  All assays reported less reactivity of goose IgY/IgY(ΔFc) with 
human PBMCs and neutrophils compared to mammalian IgG and positive control 
mitogens.  These results further support the lack of reactivity of avian IgY in the 
mammalian system and the benefits of safely using IgY as a treatment in the mammalian 
system.   
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CHAPTER I 
INTRODUCTION 
Avian Immune System 
Though the main objective of the avian immune system remains the same as that 
of the mammalian immune system, to prevent any foreign antigen from causing an 
infection, and to keep internal antigens in check, the two systems are structured and 
function differently.  Most research completed to understand, the avian immune systems 
has utilized the chicken as a model system; consequently the most is known about the 
immune system of the galliformes (land fowl) order of birds.  Despite being closely 
related to other orders of birds, such as the anseriformes (waterfowl, e.g., geese and 
ducks), not everything discovered in chickens can be directly applied to the immune 
systems of all birds.  The primary lymphoid organs of the avian immune system are the 
thymus, bone marrow, and the bursa of Fabricus (BF).  The secondary lymphoid organs 
include the spleen, harderian gland, germinal centers, and other diffuse lymphoid tissues 
[1].  One major difference between the avian and mammalian immune system is the 
presence or absence of lymph nodes.  Chickens are reported to not have lymph nodes, 
while researchers have identified what are believed to be lymph nodes in ducks [2].  
Lymph nodes are the primary site of antigen presentation in the mammalian immune 
system and are crucial for the development of a proper immune response.  It is unknown 
for sure where this crucial interaction between antigen and immune cell takes place in 
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chickens.  It is speculated to occur locally at the site of infection, probably in one of the 
many lymphoid aggregates of the mucosal tissue [3].   
The thymus is the primary location for the development of T-lymphocytes (T-
cells), including initial development and maturation.  There is also a small percentage of 
B-lymphocytes (B-cells) in the thymus that is dependent on the age of the bird [1].  The 
BF is an organ unique to the avian immune system and is the sole site of B-cell 
differentiation and synthesis [4].  Glick and Chang have shown that removal of the BF 
results in the elimination of the antibody response in the majority of bursectomized 
chickens [5].  Bursectomized birds, unlike thymectomized birds, lack immunoglonulins, 
splenic germinal centers, plasma cells, and an antibody response, but were capable of a 
graft-versus host response, and produced normal numbers of circulating small T-
lymphocytes [6]. The bone marrow is the source of precursor stem cells for both B and T-
cells that then migrate to the BF and thymus respectively for further differentiation.  In 
the avian system the spleen is the primary site for plasma cell proliferation and memory 
B-cell maintenance [7,8].  The spleen is not only an important organ for lymphocyte 
development, but is also the location for granulocyte production, antibody production, 
and is important for antigen processing [1].  Some important lymphoid organs within 
these mucosal lymphoid tissues are the Peyer’s patches and harderian gland.  The Peyer’s 
patches are a location of lymphoid cell accumulations in the gastrointestinal tract and 
appear to be a major site for IgA responses to pathogenic organisms and undigested 
antigens [9].  The harderian gland is part of the head associated lymphoid tissue located 
behind the eyeball within the orbit.  Plasma cells make up a large percentage of the cells 
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in this gland, serving as the major antibody secreting gland of the lacrimal apparatus and 
are important in development of vaccine immunity [1,10].   
The avian immune response can be divided into two major parts, the innate and 
adaptive immune response.  The innate immune response is activated during the acute 
phase of infection and involves both a non-specific barrier protection and a portion of the 
response that is specific, not to individual pathogens, but to classes of pathogens.  Some 
examples of non-specific physical barriers that are part of the avian immune system 
include the skin, mucus membranes, and gastric juices.  The more specific portion of the 
innate response depends on the cellular components of the innate immune system 
including natural killer cells, monocytes/macrophages, and heterophils.  The innate 
cellular components of the avian immune system are simplified compared to the 
mammalian system, lacking eosinophils, basophils and neutrophils [3].  Avian 
heterophils are functionally similar to mammalian neutrophils being the predominant cell 
responding to innate inflammatory reactions in chickens [11].  Heterophils are highly 
phagocytic; most of the antimicrobial activities are carried out through phagocytosis and 
the release of granules within the cell [11].  Some of the innate avian immune cells also 
have receptors present on their surfaces and endosomes called pattern recognition 
receptors (PRRs), which can recognize different types of antigens referred to as pathogen 
associated molecular patterns (PAMPs).  One well studied group of PRRs are the Toll-
like receptors (TLRs).  Research suggests that mammals and chickens have different TLR 
repertoires, but the basic function is the same [12-14].  The interaction between PRRs and 
PAMPs can influence the production and release of cytokines, chemokines, and other 
inflammatory mediators by immune cells that influences all subsequent steps of the 
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immune response.  Cytokines and chemokines are a broad group of secreted intracellular 
messengers that serve to coordinate both the innate and adaptive immune responses as 
well as immune cell development and homeostasis.  These intracellular messengers can 
be secreted by many different cell types and can exert their regulatory effects on immune 
system cells, hematopoietic stem cells, and non-immune tissues to aid in immune host 
defense and homeostasis.  Some of the major groups of cytokines include interferons 
(IFNs), interleukins (ILs), and colony stimulating factors (CSF).  Compared to the 
mammalian system, fewer cytokines and chemokines have been identified in the avian 
system [15,16].  The human genome has 129 cytokine and chemokine sequences, while 
the chicken has only 77 [17].   
If the innate immune response is unable to clear the antigen, activation of the 
adaptive immune response is required.  Activation of the adaptive immune response will 
also result in the formation of immunological memory, leaving the bird with a potential 
advantage in the future.  The innate response is able to influence the adaptive immune 
response through cytokines, chemokines, and other inflammatory mediators.  A key 
bridging point between the two responses is the presentation of antigen in the context of a 
major histocompatibility complex (MHC) on the surface of antigen presenting cells 
(APCs) such as dendritic cells (DCs) and macrophages (MOs).  There are other cells that 
act as phagocytes within the avian system: thrombocytes (functional homologs of 
mammalian platelets, which are absent from birds) [18,19], and heterophils.  Depending 
on the type of antigen, either the cell-mediated or humoral immune response is 
preferentially developed against the antigen.  T- and B-cells are the primary effector cells 
of the adaptive immune response and are responsible for the cell-mediated and humoral 
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immunity.  The preferential development of either the cell-mediated or humoral 
responses are driven in part by two subsets of CD4+ helper T-cells: Th1 and Th2.  
Expansion of one the T-cell subsets over the others are dependent on the cytokines in the 
milieu during the immune response.  The Th1/Th2 CD4+ T-cell subset paradigm has been 
demonstrated in chickens [20].  What remains unclear however is whether other T-cell 
subsets (e.g. Treg, Th17 and Th9), exist within the avian immune system.  It is thought in 
the avian immune system typically an endogenous antigen is recognized by the CD8+ T-
cell subset, in the context of MHC I, leading to activation of the cell-mediated immune 
response.  CD8+ T-cells become cytotoxic, capable of antigen-specific killing of infected 
cells.  An exogenous antigen activates CD4+ T-cell subset, when presented on the surface 
of an APC in the context of MHC II.  CD4+ T-cell subsets are termed T helper cells, they 
are responsible for helping with antigen-specific activation of B-cells, aiding in the 
humoral immune response along with providing help to macrophages, NK cells, and 
CD8+ T cells [3].  The end result of the immune response is clearance of the pathogen and 
development of memory.   
The effector cells of the humoral immune response are antibody producing B-
cells with antibodies carrying out the major functions of the humoral response.  Within 
the avian immune system there are three classes of immunoglobulins (IgM, IgA, and 
IgY), all of which have been identified immunochemically [21] and genetically as 
homologs to mammalian IgM, IgA, and IgG [22-24].  Avian IgM is structurally and 
functionally homologous to mammalian IgM; it is present in the serum as a high 
molecular weight pentamer and is the first antibody produced during a primary antibody 
response.  IgA is also similar to its mammalian homolog and is able to be found in the 
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serum of birds, bile, and tears.  IgY is generated typically during a secondary antibody 
response and behaves in part like mammalian IgG and mammalian IgE.  In anserifomes 
birds there is an additional structurally different isoform of IgY that is termed IgY(ΔFc).  
During egg formation, IgY in the serum is selectively transferred to the yolk via a 
receptor on the surface of the yolk membrane specific for IgY translocation, transferring 
immunity from the hen to the developing embryo [25-28].  The amount of IgY 
transferred is directly proportional the IgY serum concentration [27].  Both avian IgA and 
IgM can be found in the egg white [29].  So far there have not been any identified avian 
homologs of mammalian IgD or IgE [23].   
As mentioned previously the organs in the avian immune system that are 
responsible for antibody production differ from those utilized in the mammalian system.  
The primary lymphoid organ responsible for the differentiation of stem cells into B-cells, 
as well as diversification, is the BF [4].  The spleen is where plasma cells and memory B-
cells can be found.  There are various mechanisms used by the immune system to 
generate the necessary antibody diversity, the primary mechanisms used do differ 
between the mammalian and avian systems.  In the avian system the primary antibody 
repertoire is generated primarily by a process of somatic gene conversion and by somatic 
point mutations.  Committed precursor B-cells enter the BF with fully rearranged 
immunoglobulin genes and rely on upstream pseudogenes to create diversity for both 
light and heavy chains [30-32].  Antibody gene rearrangement in birds takes place in the 
developing embryo during a 10 day window prior to hatching.  The antibody light (L) 
chains are mostly of one type (λ) [33], meaning the genomic L chain locus is made up of 
one constant region (CL or Cλ).  The rest of the L chain locus is made up of a single 
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unique junctional region (JL), which undergoes rearrangement to the adjacent function 
variable region gene (VL) [33].  The same VL and JL segments are used in all B-cells 
during VJL rearrangement, limiting the diversity that can be gained within the L chain 
from the process of gene rearrangement.  A similar organization has been characterized 
for the heavy (H) chain locus.  There is one V region (VH), a single J segment (JH), used 
in all B-cells, and approximately 15 function diversity (DH) segments [24,34].  The H 
chain immunoglobulin gene loci also contain constant region genes μ, ν, and which allow 
for the production of IgM, IgY and IgA respectively.  Because there are multiple DH 
segments there is a minimal amount of junctional diversity generated from VDJH 
rearrangement.  There is potential for rearrangements with fused D-D elements, due to 
the sequence homology between the DH segment sequences [23].  Unlike in the bone 
marrow of the mammalian system there is no specific order in which the rearrangements 
need to take place; rearrangement of one chain is not dependent on the other.  In fact 
VDJH and VJL rearrangements have been detected at the same time in the developing 
embryo [35].   
After successful gene rearrangement primary antibody diversity is generated 
through the use of pseudogenes and somatic gene conversion.  Both the immunoglobulin 
L and H chain gene loci have pseudogenes upstream from the VL and VH regions.  
Upstream from VL is a group of appxomimately 25 psdeudogenes (ΨVL), and upstream 
from VH there are approximately 80 pseudogenes (ΨVH) [36].  These gene segments are 
defined as pseudogenes because they typically lack the promoter sequences required for 
transcription, have a truncated 5’ or 3’ coding region, or lack the necessary 
recombination signal sequence (RSS) [33].  The process of somatic gene conversion 
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starts approximately 15-17 days after the immature B-cells migrate to the BF [37].  
Diversity is ultimately generated when sequences derived from the upstream pseudogenes 
replace homologous sequences within the V region of rearranged VJL or VDJH genes and 
undergo gene conversion [38].  After gene conversion is complete, the B-cells have 
reached the end of their time in the BF and migrate into the periphery.  B-cells usually 
start to migrate from the BF in the last few days before the bird hatches.  At first the 
percentage of cells migrating from the BF is low.  After hatching about five percent of 
bursal B-cell migrate each day into the periphery through the blood and then into the 
spleen, thymus and caecal tonsils, where they will eventually produce antibodies and be 
active in the humoral immune response [36,39].  The remaining percentages of bursal B-
cells end up dying in the bursa during various steps in development due to autoreactivity, 
or nonproductive H and L chain rearrangements.  However, B-cells deaths are rarely due 
to the process of gene conversion, that process is ~98% successful [40,41].  It has been 
observed that by the time baby chickens reach the age of four weeks a sufficient number 
of B-cells have migrated out of the BF.  At that point the B-cell immune system is 
considered mature in the periphery, resulting in involution of the BF [42].  Once the B-
cells are in the periphery, the spleen is responsible for maintenance and proliferation of 
plasma cells and memory B-cells.   
 
Function and Structure of IgY Antibodies 
 Structural and functional research shows avian IgY is similar to mammalian IgG.   
Avian IgY is the functional equivalent of mammalian IgG within the avian immune 
system, acting as the major system antibody responsible for defense against infectious 
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diseases.  Unlike IgG, full length IgY is also able to sensitize tissues to anaphylactic 
reactions [43].  Structurally avian IgY is similar to mammalian IgE based on size and 
number of exons.  IgY is classified as a low-molecular weight (LWM) immunoglobulin, 
thus it is made up of two H chains and L chains with a molecular mass of ~180kDa [44].  
Each of IgY’s L chains consists of one variable and one constant domain with a 
molecular weight of ~18kDa.  The H chains of IgY have one variable domain and four 
constant domains denoted Cν1-Cν4, with a molecular weight of ~65kDa [44].  As was 
mentioned previously, IgY is structurally similar to mammalian IgE.  Both of these 
antibody’s H chains have four constant domains and are lacking a hinge region. It is also 
the H chains that structurally differentiates mammalian IgG from IgY.  The H chains of 
mammalian IgG have only three constant domains (Cγ1-Cγ3) with molecular weights of 
~59kDa each, causing the molecular weight of IgG to be only ~159kDa, less than that of 
IgY.  Sequence comparison between IgG and IgY has shown that the Cγ2 and Cγ3 
domains of IgG are closely related to the Cν3 and Cν4 domains of IgY, while the 
equivalent Cν2 domain is absent in the IgG H chain [45,46].  The Cν2 domain that is 
present in IgY is thought to have been replaced by the hinge region in IgG [23].  This is 
supported by the observation that the hinge region of IgY is much less developed 
compared to IgG, and the flexibility of IgY is also decreased compared to IgG [45].  The 
lack of a developed hinge region in IgY may account for some of the differences in 
function between the two types of antibody.  
 There is an additional isoform of IgY that can be found in anseriformes birds, 
which lacks two C-terminal constant domains (Cν3-Cν4) of the H chain.  This isoform of 
IgY is referred to as alternatively spliced IgY or IgY(ΔFc) and has a molecular weight of 
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~120kDa.  IgY(ΔFc) and full length IgY may coexist in an individual organism as they 
do in anseriformes birds, or one form may be produced exclusively.  For example, 
chickens only produce full length IgY.  Both full length IgY and IgY(ΔFc) are products 
of a single gene generated by alternate pathways of mRNA processing [47,48].  Despite 
being from the same genetic source IgY and IgY(ΔFc) do have some functional 
distinctions.  During an immune response the IgY(ΔFc) isoform is found later in the 
immune response than full length IgY [49].  In the avian immune system, full length IgY 
is able to fix complement and sensitize tissues to anaphylaxis, but both of these immune 
functions are not carried out by IgY(ΔFc) [49].  These functional differences between the 
isoforms are most likely due to the alternatively spliced isoform lacking the two terminal 
Fc domains.  This limits IgY(ΔFc) to functions that do not require secondary effector 
functions such as virus neutralization.  It is even possible that IgY(ΔFc) was tolerated 
evolutionarily because of its inability to sensitize the host birds to IgE-like reactions 
leading to less host damage.   
 
Physiochemical Properties of IgY and IgY(ΔFc) Antibodies 
 Other properties of IgY that differ from mammalian IgG include β-sheet content, 
hydrophobicity and isoelectric point.  The β-sheet content of IgY, especially in the 
constant domain, is lower than that of IgG [50].  Decreased β-sheet content has the 
potential to cause a more disordered conformation in IgY leading to a less stable antibody 
than IgG.  IgY is also more hydrophobic than IgG.  This is due in part to the fact that the 
Fc fragment of IgY is larger than that of IgG, and the fact that the Fc portion of the 
antibody is the most hydrophobic part of the antibody molecule.  Experiments completed 
  
11 
 
comparing the kinetics of either IgG or chicken IgY interacting with latex particles under 
varying conditions further support the increased hydrophobicity of IgY versus 
mammalian IgG [51].  The isoelectric point of IgY is in the range of 5.7 to 7.6, lower 
than that of IgG [52].   
 The use of IgY as a potential passive therapeutic is dependent on the ability of the 
antibody to remain stable and active when exposed to a variety of environmental 
conditions including heat, pH, and proteolytic enzymes.  When compared to rabbit IgG, 
IgY is much less stable during acid denaturation.  IgY has been found to be stable in a 
range between pH 4 to pH 11, but above or below this range IgY activity decreases 
[53,54].  IgY activity is decreased at a pH of 3.5 and completely lost at pH 3, while rabbit 
IgG activity is not lost until pH 2 [50,55].  The stability at harmful pH’s can be improved 
by adding different carbohydrates of sugars to act as stabilizers [56,57].  Temperature is 
also a threat to the activity of IgY.  Researchers have reported that as temperature 
increases, IgY activity decreases.  Heating IgY to a temperature of 60-65ºC will result in 
a minimal loss of activity, but the major decrease in activity is reported at temperatures of 
70ºC or higher, when heated for more than 15 minutes [50,53,55].  The addition of sugars 
can help IgY to maintain activity at higher termpatures in the range of 75-80ºC [57].   
IgY is also susceptible to proteolytic cleavage by enzymes such as pepsin, trypsin, 
and chymotrypsin.  In general, IgY has been found to be more resistant to the activity of 
trypsin and chymotrypsin than that of pepsin.  Almost all IgY activity is lost after 
digestion with pepsin while, on the other hand IgY remains active even after eight hours 
of incubation with trypsin or chymotrypsin [53].  The sensitivity of IgY to pepsin seems 
to be dependent on the pH and enzyme to substrate ratio [53].  Different variations of pH 
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and enzyme to substrate ratio will yield different effects on IgY activity.  Overall, IgY is 
more susceptible to all three of these proteolytic enzymes that IgG.  These differences in 
susceptibility could be related to the structural differences between the two antibodies, 
including the lower β-sheet content of IgY along with the lack of a hinge region [50].  
Both of these structural characteristics have an impact on the overall properties and 
stability of the IgY molecule.   
 
Advantages of Passive IgY Antibody Immunotherapy 
 Avian IgY antibody treatments have many advantages over traditionally used 
passive antibody treatments, some of which stem from the phylogenetic distance between 
the mammalian and avian species. The phylogenetic distance leads to an increased 
immune response in birds when compared to mammalian antibodies.  The IgY produced 
has a higher avidity for mammalian antigens, and recognizes different epitopes compared 
to mammalian antibodies, creating a unique antibody repertoire [58,59].  Even when 
mammals and birds are identically immunized often times different antibody specificities 
will develop in birds than mammals.  Di Lonardo et al. showed through epitope mapping 
that when rabbits and chickens were immunized with the same antigen, in this case 
human papilloma virus type 16E7 oncoprotein (HPV16E7), the resulting antibodies 
recognized different peptides[58].  Eight HPV16E7 peptides were used for the epitope 
mapping; the chicken antibodies reacted to all eight peptides, while the rabbit antibodies 
only reacted with two peptides [58].  In another example, eggs from immunized chickens 
were used as a source of IgY antibodies against the insulin receptor of rats, as a means to 
gain more information about the function and structure of the insulin receptor.  Previous 
  
13 
 
results utilizing rabbit antibodies against the α-subunit of rat insulin receptors did not 
entirely mimic the insulin resistance response seen in patients that naturally produce 
antibodies against insulin receptors.  In order to better mimic the natural human 
syndrome, chicken IgY antibodies against insulin receptors were generated.  The 
properties of the IgY antibodies were similar to those of the antibodies found in the 
human disease and caused the inhibition of insulin binding, stimulated glucose oxidation, 
and autophosphorylation of the insulin receptor [59].  Rabbit antibodies of the same 
specificity failed to mimic all of the same effects as the IgY antibodies, mainly insulin 
binding was not prevented [59].  These are just two examples that clearly demonstrate the 
avian IgY antibodies ability to recognize different epitopes than mammalian antibodies, 
regardless of the origin of the antigen.  For some mammalian antigens IgY antibodies 
have increased binding specificity and sensitivity compared to mammalian antibodies.  
IgY can be used to make antibodies against conserved antigens within the mammalian 
system, in some situations there may be no other option if the antigen is too highly 
conserved [60]. Using IgY antibodies from the eggs of immunized birds offers 
researchers access to a different antibody repertoire than what can be achieved with the 
mammalian techniques currently used.   
 A key advantage to the use of avian IgY antibodies is being able to utilize the egg 
as the source of the antibodies.  Eggs can be easily harvested from laying birds, 
eliminating the need for bleeding animals representing a non-invasive and more humane 
method of obtaining antibodies that meets current regulations regarding animal use in 
research.  Not only is it less invasive, but an equivalent or greater amount of antibodies 
can be isolated from the egg yolks of a chicken, duck, or goose egg compared to what can 
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be isolated from the serum of rabbits or other animal sources of antibody.  The amount of 
IgY purified from a chicken egg can vary depending on age and breed of the hen, along 
with the antigen used for injection, from 60-150mg per egg [61,62].  Based on the laying 
habits of chickens the average monthly antibody production is in the range of 1000 to 
2800 mg [37].  Goose eggs are larger than chicken eggs increasing the amount of IgY 
that can regularly be purified from a single goose egg to 500mg.  In comparison, to 
isolate 200mg of mammalian IgG from rabbit serum it would take approximately 40mL 
of blood which is total amount of IgG available for the month [37].  Because IgY levels 
in eggs can be influenced by bird age, studies have been completed comparing laying 
patterns to IgY content of eggs from laying hens over an extended period of time.  When 
laying hens were monitored for a two year period, there was a decline in the laying 
capacity of the hens in the second year.  However, there was also an increase in the total 
IgY per egg, balancing out the decrease in egg numbers [62].  Antigen specific IgY titers 
remained stable during the two year time period and the IgY was functional [62].  These 
findings are supported by the observations of Trot et al. that older hens have higher IgY 
titers compared to younger hens.  When taking into consideration both egg mass and 
laying frequency, young hens in the study had a 1.3 fold increase in total egg mass 
compared to older hens, but this difference was offset by a 1.5 fold increase in IgY titers 
in older chickens [61].  Not only can eggs easily be collected from their avian sources, 
IgY can also easily be isolated from the egg yolk.  Throughout literature various methods 
have been described to isolated IgY from the egg yolk, but all utilize one or more the 
following basic lab procedures: precipitation, chromatography, and/or ultracentrifugation.  
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Some labs are extracting IgY from eggs on an industrial scale, supporting the potential 
large-scale production of IgY therapeutics [63,64].   
 Most biological effector functions of immunoglobulins are activated by the Fc-
region.  As described above, the Fc region is where the major structural differences 
between IgG and IgY are located; which leads to a difference in Fc dependent functions 
between the mammalian IgG and avian IgY molecules.  This difference can be used to 
prevent interferences in immunological assays as well as adverse reactions within the 
body caused by rheumatoid factor (RF), complement activation, human anti-murine 
antibodies (HAMA), or binding to human and bacterial Fc receptors.  There are 
antibodies within the body that react with the Fc portion of mammalian IgG antibodies, 
one example is RF.  Most of the time RF is an autoantibody associated with rheumatoid 
arthritis (RA), but it can be found in the patients with other diseases and in the blood of 
healthy individuals [65].  HAMAs form often when antibodies are used for treatment or 
imaging.  More specifically, the murine antibody is seen as a foreign protein by the 
human body, which triggers an immune response resulting in the formation of HAMAs.  
In some cases HAMAs have also been found in the serum of patients who have not been 
treated with antibodies [66].  The HAMA response can persist in the blood for several 
months, and can be easily reactivated if memory B-cells are formed.  This response can 
interfere with assays used in diagnosis and/or surveillance of disease and cause 
potentially painful symptoms for the patients.  Attempts have been made to prevent the 
HAMA response by making humanized antibodies through replacement of the Fc portion 
of murine antibodies with the constant region of human antibodies.  Some of these 
engineered antibodies are only 10% murine or even “fully human.”  These engineered 
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antibodies have protein epitopes that can be seen as immunogenic by the human immune 
system and ultimately cause an antibody response by the body.  This response is referred 
to as an anti-drug antibody response (ADA).  The HAMA/ADA responses within the 
body can result in a variety of symptoms from more mild allergic reactions, generalized 
pain, hponatremia, fever, rigors, chills, rash, paresthesia, weakness, chronic refractory 
postural hypotension [67,68], to hypersensitivity reactions that range from serum sickness 
with urticarial and bronchosapsms [68-72], to anaphylactic shock [73-75].   
HAMA/ADAs can be classified as either binding antibodies (Bab) or neutralizing 
antibodies (Nabs) depending on if they alter the pharmacokinetics of the antibody 
treatment and/or lead to symptomatic reactions in the body [76-79].  Babs bind to sites on 
the antibody that do not directly interfere with the ability of the antibody to interact with 
the intended target of the antibody.  They can affect the pharmacokinetics, specifically 
the clearance of the antibody treatment from the body before it can function properly [79-
81].  Nabs bind to sites on the antibody that are important for ligand-receptor interaction 
thereby inhibiting antibody function; this can cause diminished efficacy and lead to 
failure of the treatment [82-84].  Nabs are primarily of the IgG isotype and more 
commonly cause life-threatening conditions that Babs [73].  Using IgY antibodies as an 
alternative to current IgG antibody treatments on the market comes with a decreased risk 
of adverse reactions because IgY antibody does not interact with human RF or cause 
HAMA/ADA responses [84-86].  IgY can also be used to replace mammalian IgG in 
immunoassays to avoid interference from RF or HAMA/ADAs produced during 
treatment with mammalian IgG [86,87].  Reduced interference in immunoassays will also 
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decrease the number of false positive results and unnecessary medical procedures done 
because of inaccurate test results.   
 The complement pathway is another example of an Fc- dependent function that 
IgY antibodies are unable to activate because of the distinctive structure of their constant 
region.  Within the avian immune system IgY antibodies binding to antigens are able to 
bind to activate the complement system.  The same is not true when avian IgY antibodies 
are placed in human immune conditions.  Avian IgY antibodies do not activate the human 
complement system [88].  In the mammalian system, under normal conditions antibodies 
react to antigen to form an antibody-antigen complex.  The Fc portion of the antibody can 
then activate the complement system and lead to recruitment of inflammatory cells, 
opsonization of pathogens, and killing of pathogens.  When the complement pathway is 
inappropriately activated it can lead to unnecessary inflammatory reactions.  The 
anaphylatoxins C4a and C5a products of the complement pathway are often responsible 
for initiating parts of these inflammatory responses.  The anaphylatoxins are able to 
stimulate mast cells to trigger IgE-independent histamine release as well as TNF-α 
release [89].  This can mimic allergic shock depending on the number of mast cells 
involved [90,91].   
A serum sickness-like illness can also develop depending on the number of 
complement immune complexes formed during the course of treatment.  Serum sickness 
can also result from complement-binding immune complexes, which can lead to 
activation of leukocytes and then to widespread tissue damage.  Though the disease is 
usually self- limiting, after a second dose of antigen the illness will follow the same 
kinetics as a secondary immune response.  C5a also acts directly on neutrophils and 
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monocytes to increase their adherence to vessel walls, their migration towards sites of 
antigen depositions, and their ability to ingest particles [89] further contributing to the 
progression of serum sickness.   
Complement activation is dependent on the carbohydrate determinants in the Fc 
region of antibodies; the composition of antibody subclasses IgG1 and IgG3 make them 
most effective at complement activation [92,93].  IgY is unable to initiate the 
complement cascade in mammals due the difference in the Fc portion of the antibodies.  
IgY is thought to be lacking the necessary carbohydrate determinants to activate the 
complement pathway.  This prevents both complement-mediated and antibody dependent 
cell-mediated lysis from taking place in the presence of IgY [37].  IgY therapeutics have 
the potential to avoid many of the adverse reactions, including unnecessary inflammatory 
reactions, in patients caused by mammalian IgG activation of the complement pathway.  
The activation of the complement pathway by IgG can also interfere in immunological 
assays, causing problems with background and test result errors.  The lack of complement 
pathway activation by IgY also makes it a useful reagent in immunological assays, 
especially those that utlize serum, decreasing the background and reporting errors 
[88,94].   
 There is evidence that IgY, depending on the source, does not interact with 
bacterial proteins that are immunoglobulin Fc-binding.  The most well-known of these 
proteins are Staphylococcal protein A and Streptococcal protein G.  These proteins are 
able to bind to the Fc portion of IgG from many mammalian species [95,96].  The 
interaction between the bacterial proteins and IgG is utilized in purification assays and 
immunoassays.  Problems can arise from this interaction depending on the assay and 
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specimen leading to false positives.  Results of initial research using chicken antibodies 
reported that IgY does not react with Staphylococcal protein A Streptococcal G [95-98].  
There have been conflicting results regarding whether or not IgY from anseriformes birds 
interacst with bacterial Staphylococcal protein A and Streptococal protein G.  Research 
by Kronvall et al., using various methods, report that IgY from anseriformes birds does 
not interact with Staphylococcal protein A or Streptococcal protein G [97].  In some 
studies duck IgY has been reported to bind strongly to Staphylococcal protein A, but 
poorly to Streptococcal protein G in Sepharose affinity columns [2].  A more recent study 
completed by Justi-Valliant et al. compared the reactivity of immunoglobulins from 
various avian and mammalian species with Staphylococcal protein A and Streptococcal 
protein G, and other bacterial proteins.  In this study, using a direct ELISA, duck IgY was 
found to react with Staphylococcal protein A while chicken IgY was unreactive.  Overall, 
direct use of ELISA demonstrated that duck IgY reactivity was less than that of many 
mammalian species [99].  When tested via sandwich ELISA, duck serum did not react 
with Streptococcal protein G, and chicken IgY was also unreactive.  By contrast all 
mammalian species were reactive with Sreptococcal protein G.   
The interaction of avian IgY antibodies with bacterial Staphylococcal protein A 
and Streptococcal G is most likely not Fc mediated, as it is in mammals, because of the 
difference in the Fc portion of the antibodies between avian IgY antibodies and 
mammalian IgG antibodies.  This is especially true for IgY(ΔFc) produced by 
anseriformes birds, which is lacking both CH3 and CH4 domains.  It is more likely that 
IgY interacts with the bacterial proteins through the CH1 and CH2 domains of the 
immunoglobulin, although some involvement of the other domains cannot be ruled out.  
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Differences in reactivity between chicken IgY, duck IgY, and potentially other 
anseriformes birds could be due to differences in the histidine (His) content of H chains 
of the two avian species.  Research with human IgG suggests that His residues in the Fc 
region are important in binding to protein A [2].  Duck IgY H chains have eight unique 
His residues compared to chicken IgY: four in CH1, one in CH2, two in CH3, and one in 
CH4.  Most likely to be involved in binding to Staphylococcal protein A are those in CH1 
and CH2 [2].  Using avian IgY antibodies in assays is advantageous because of the lack of 
interaction between avian IgY antibodies and bacterial proteins that are Fc binding.  This 
lack of interaction can lead to a reduction in the interference problems in assays seen with 
mammalian IgG.   
 
Passive Immunization 
 Passive immunization makes use of the ability of artificial passive immunity to 
treat or prevent a foreign attack- often infectious agents.  In this type of immunity, 
antigen- specific antibodies or serum from another source, typically an immune human or 
animal, is given to another individual for protection.  The protection conferred is 
immediate and will last as long as the transferred antibodies remain in the recipient’s 
body.  Passive antibody therapeutics have been around since the late 19th-20th centuries 
with pioneering research done by Robert Koch, Emil von Behring, and Paul Ehrlich. This 
research started with the observation that blood from rats who were resistant to anthrax 
was able to kill the anthrax bacterium in later experiments [100].  These researchers 
worked to develop products termed antitoxins, antibodies, and magic bullets, all the 
predecessors of today’s monoclonal antibody therapeutics [100,101].  Advancement in 
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technology led to the design of intravenous immune globulin (IVIG).  In this process, 
antibodies from patient’s serum were isolated and then used to treat immune and 
infectious diseases [102-104].   
A major discovery was made in 1975, with Kohler and Milstein’s development of 
a method for the isolation of monoclonal antibodies from hybridoma cells.  Kohler 
identified how to obtain antibodies from mortal B-cells in culture, while his colleague 
Milstein found a way to transform myeloma cell lines and promote cell fusion.  Joining 
together they generated a method for fusion of immortal myeloma cells and antibody 
producing B-cells that secrete a single monoclonal antibody recognizing a specific 
antigen [105-107].  The first therapeutic monoclonal antibody approved by the Federal 
Drug Administration for human use in 1986, was murononab, a murine derived antibody 
used for acute organ rejection [107].  Since then the field has accelerated quickly with 25 
therapeutic antibodies currently in clinical use and many more in development.  
 Most therapeutic antibodies used today are of murine origin, most likely due to 
the early development of mouse hybridoma technology.  But the use of murine antibodies 
has its limitations.  The efficacy of murine- derived antibody therapeutics is challenged 
by their potential for high immunogenicity in humans.  The HAMA response after murine 
monoclonal antibody treatment in severe cases can result in anaphylaxis.  Not only does 
the HAMA response adversely affect the patients, but the antibody can also be 
inactivated and eliminated from the body before it can function properly.  Murine 
antibodies can generate a less than ideal protection in humans, reacting with epitopes that 
are not protective [101].  There has been an increasing interest in the use of avian 
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antibodies as passive immune therapeutics.  Many of the weaknesses of current 
therapeutics can be resolved by using avian IgY antibodies.   
 
Passive IgY AntibodyTreatments 
 Current research using polyclonal avian IgY antibodies as a potential passive 
antibody treatment is ongoing in both the veterinary and human fields.  The goal of a 
majority of these treatments is to establish protective immunity in the host by delivering 
pathogen- specific avian IgY antibodies to the host.  Polyclonal antibodies have been 
made against a variety of infectious disease agents including bacteria, viruses, fungi, 
toxins, and venoms.  Their effectiveness has also been tested in a number of disease 
models and human trials.  A few representative examples are reviewed below. 
Pseudomonas aeruginosa 
The most successful clinical application of avian IgY antibodies has been the 
prevention of Pseudomonas aeruginosa (P. aeruginosa) colonization in cystic fibrosis 
(CF) patients.  CF is a hereditary, life threatening disorder with repeated respiratory 
infections and malnutrition as main clinical manifestations [108].  Chronic lung 
infections with P. aeruginosa are a major cause of morbidity and mortality in CF 
patients, and are accompanied by a more rapid deterioration in lung function.  Usually 
these P. aeruginosa infections are treated with antibiotics, which can help to reduce, and 
sometimes clear the infection.  However, the infection often continues to reappear until 
the patient is chronically infected and the P. aeruginosa becomes impossible to eradicate 
[109-115].  Chronically infected patients need to be continually treated with antibiotics; 
this continual treatment can lead to secondary infections, bacterial resistance, allergic and 
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toxicity reactions, and negative effects on commensal flora [116-119].  Anti- P. 
aeruginosa IgY has been and is continuing to be researched as a complement and stand-
alone treatment for P. aeruginosa in CF patients.  It is impossible to eradicate P. 
aeruginosa once a person becomes chronically infected.  As a short term treatment anti-
P. aeruginosa IgY could be used to prolong the amount of time between infections.  As a 
long-term treatment avian IgY antibodies could be used to decrease the number of P. 
aeruginosa infections and prolong the onset of chronic P. aeruginosa infection.  
 In vitro studies have already established the potential of the anti- P. aeruginosa 
IgY antibodies to prevent P. aeruginosa infections by blocking the ability of the bacteria 
to adhere to the epithelium in the oropharynx and thereby prevent the bacteria from 
entering the lower airways [66,120].  For in vivo research Kolberg et al. developed P. 
aeruginosa specific avian IgY antibody by immunizing white leghorn hens with 
formaldehyde-fixed P. aeruginosa [120].  Eggs were collected from immunized hens and 
IgY was isolated from the egg yolks.  The anti- P. aeruginosa IgY was then prepared in 
such a way that CF patients could use it as a mouth rinse.  Experimental group CF 
patients were instructed to gargle with the IgY mouth rinse for two minutes and then 
swallow it every evening after their final meal and brushing teeth.  The goals of this in 
vivo study were two-fold.  First, to see if daily use of anti- P. aeruginosa IgY could 
prolong the length of time between the first and second P. aeruginosa colonization in 
patients that are not yet chronically infections.  The second goal of this research was 
centered on long-term treatment and if continuous use of the anti- P. aeruginosa IgY 
mouth rinse could decrease the intermittent colonization rate and prevent chronic 
infection, ultimately decreasing the need for antibiotics.  Based on results from sputum 
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samples collected from CF patients throughout the study, the amount of time between the 
start of treatment and the next P. aeruginosa positive culture was longer in patients 
treated with anti- P. aeruginosa IgY than the control treatment.  Though the trend was 
obvious, the difference was not significant.  In long-term study, the 10 CF patients in the 
experimental group participated for an average of 57 months and the 21 control group CF 
patients participated for an average of 36 months.  There was a total of only 14 positive 
cultures in the anti- P. aeruginosa IgY treatment group out of a total 315 (4.4%) cultured 
that were positive for P. aeruginosa.  In comparison, the control group patients had 105 
positive cultures out of the 315 collected during the study (18.7%) [120].  Also, none of 
the 13 patients in the experimental group became chronically colonized with P. 
aeruginosa, while 5 of the patients in the control group did become chronically colonized 
[120].   
A similar experimental design was followed in in vivo studies completed by 
Nilsson et al. in 2008 to determine the efficacy and adverse reactions of long-term 
treatment with anti- P. aeruginosa IgY [108].  Results were similar, chronic colonization 
occurred in only 2 of the 17 CF patients treated with anti-P. aeruginosa IgY, but in 7 of 
the 23 CF control treatment CF patients [108].  The median time to reinfection after 
treatment in the control treatment group was 19 months and in the anti- P. aeruginosa 
IgY treated group it was 25 months [108].  These results support the use of anti- P. 
aeruginosa IgY as a means to decrease the number of P. aeruginosa infections over a 
given length of time and to prevent chronic P. aeruginosa infections.   
Additional studies were completed to gain more insight into the mechanism that 
leads to the decrease in colonization reported after treatment with anti-P. aeruginosa IgY.  
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It was determined that the anti - P. aeruginosa specific IgY binds to flagellin present on 
the surface of the bacteria, which may prevent P. aeruginosa in CF patients by hindering 
host infections due to reduced adherence.  The avian IgY antibodies may be able to 
directly affect adherence or indirectly reduce the bacteria’s motility [121].   
Streptococcus mutans 
 The mircobiota within the oral cavity is important in host defense, acting as a 
barrier by creating unfavorable conditions for exogenous organisms that might be 
pathogenic to the host.  Under the right conditions, some of the bacteria present in the 
mouth can cause infections, including dental caries, which are most often caused by 
Streptococcus mutans (S. mutans).  Dental caries result from interactions between the 
host, diet, and the microflora on tooth surface [122].  Virulence factors of S. mutans 
include adherence to the enamel surfaces of the tooth, production of acidic metabolites, 
and the ability to synthesize extracellular polysaccharides [123,124].  Specifically, 
glucosyltransferases (gtf) have been shown to be one of the major virulence factors in the 
pathogenesis of dental caries [125,126].   
Passive treatments administered topically [127,128], by local injection [129-131], 
intranasally [132,133], and orally [134-138], specifc for S. mutans have all been 
previously tried with varying degrees of success in both animal models and human trials.  
The most direct evidence supporting the potential for S. mutans specific avian IgY 
antibodies derives from the research of Michalek et al. and Filler et al [134,136].  
Michalek et al. was able to show in an experimental animal model of dental caries that 
oral administration of S. mutans- specific bovine milk antibodies was able to reduce 
caries.  In humans it was reported that those who used a mouth rinse with S. mutans 
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bovine milk antibodies had an initial decrease in the number of recoverable S.mutans 
[134].   
 To test the potential success of an avian IgY antibody passive treatment for dental 
carries caused by S. mutans, Hatta et al. isolated avian IgY antibodies specific for the 
whole bacteria.  The S. mutans specific IgY was formulated into a mouth rinse to be used 
by volunteers as a way to prevent S. mutans colonization in the mouth.  Levels of S. 
mutans decreased in volunteers who gargled with the S. mutans specific IgY mouth rinse 
[139].  The presence of antibodies in the volunteers correlated with protection against 
caries formation.  It is likely that the polyclonal S. mutans specific IgY in the mouth rinse 
had antibodies specific to the insoluble glucans covering the surface of the bacteria, and 
less to the serotype-specific antigenic sites on the surface of S. mutans, Thus allowing the 
potential to interact with the various seroptyes of the mutans streptococci that can exist in 
human saliva and plaque [139].   
 Kruger et al. targeted the gtf virulence factor of S. mutans by developing anti-cell-
associated (CA) gtf IgY antibodies from the egg yolk of chickens immunized with gtf.  
Gtf is essential for the production of glucans by S. mutans and an important virulence 
factor.  S. mutans with defective glucan function induce markedly reduced levels of 
smooth and sulcal surface carious lesions in rats [122].  These S. mutans- specific 
chicken-derived anti-gtf antibodies were tested in desalivated rats to mimic clinical caries 
situations in patients with reduced salivation (dry mouth) due to medication, Sjogren’s 
syndrome, or other causes.  Desalivated rats given drinking water containing the anti-CA-
Gtf-IgY had significantly lower development of smooth surface and sulcal caries lesions 
compared to rats given IgY control water and sterile water.   
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Helicobacter pylori 
 Helicobacter pylori (H. pylori) infects over 50% of the population worldwide and 
is the most important etiological agent of gastroduodenal ulcers and malignancies [140].  
After oral ingestion of the bacteria, once in the gastrointestinal tract, H. pylori has 
numerous virulence factors that help it to survive and cause disease, including the ability 
to move via flagella.  The bacteria are able to produce a cytotoxin, and have adhesins on 
their surface to aid in attachment to epithelial cells.  The urease enzyme produced by the 
bacteria is one of the most important virulence factors that aids in the organism’s ability 
to colonize gastroduodenal mucosa [141].  Urease is able to hydrolyze urea into carbon 
dioxide and ammonia, permitting H. pylori to survive in the acidic environment of the 
gastrointestinal tract [142,143].  H. pylori disruption of the epithelial layer in the 
gastrointestinal tract causes various types of gastritis that can be indicative of further 
clinical outcomes, including ulcers.  H.pylori is responsible for the majority of duodenal 
gastric ulcers.  The lifetime risk of peptic ulcer development in persons infected with 
H.pylori ranges from 3% in the United States, to 25% in Japan [144,145].  Eradication of 
H. pylori drastically lowers the recurrence rates of H. pylori- associated ulcers [146].  
The goal of current H. pylori treatment is to eliminate the organism.  But, there are 
several cases where anti-microbial agents do not work efficiently enough to clear the 
infection and there is a potential for the development of resistant organisms.  This leaves 
the infected individual at risk for the recurrence of ulcers and continued pain.  There is 
still the need for H. pylori treatments that can be used alone or in conjunction with 
current anti-microbial agents.  
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 A novel passive immunization treatment for the prevention and reduction of H. 
pylori infections was created by Horie et al., utilizing current knowledge on the urease 
virulence factor of the bacteria [140].  The cross-reactivity between the anti H. pylori 
whole cell lysate antibodies, and other bacteria in the human gastrointestinal tract, can 
decrease the efficacy of the anti IgY H. pylori treatment.  This fact makes it necessary to 
develop antibodies that target specific antigens of the bacteria. A H. pylori urease- 
specific polyclonal chicken IgY antibody (IgY-urease) was isolated from the yolks of 
eggs collected from hens immunized with an aqueous extraction of purified H. pylori 
urease enzyme.  A drinking yogurt was formulated containing 1% IgY-urease along with 
Lactobacillus acidophilus and Bifidobacterium spp. [140].  The effectiveness of the IgY-
urease containing yogurt was tested in human volunteers who were positive for the 
presence of H. pylori as determined by a urease breath test (UBT).  The volunteers who 
drank the yogurt with the IgY-urease had a significant reduction in UBT values compared 
to controls, meaning the IgY-urease yogurt was effective at suppressing H. pylori 
infection in individuals previously colonized with H. pylori [140].     
 Another avain IgY antibody treatment specific for H. pylori has been tested in 
BALB/c mice.  This treatment targets a highly immunoreactive and bacteria specific 58-
kDa antigen (Hp58) that was originally identified in the whole cell lysates of H. pylori 
[147].  Polyclonal IgY was generated against the target by the immunization of White 
Leghorn hens with purified Hp58.  Eggs were collected and Hp58- specific IgY was 
isolated from the egg yolk.  IgY from non-immunized hens was used as a control.  The 
reactivity of IgY-HP58 antibody was tested by western blotting.  The IgY-Hp58 antibody 
identified the 58-kDa immunoreactive band in whole cell lysates of H. pylori using 
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western blotting.  There was no band present when egg yolk antibodies from non-
immunized hens (IgY-N) reacted with cell lysates [147].  To test the effectiveness of the 
IgY-HP58 antibody against H.pylori infection, a mouse model of infection was used.  
Mice were passively immunized with IgY-Hp58 antibodies at 1 day, 1 week, 4 weeks, or 
12 weeks post infection with H. pylori.  The highest effect of passive immunization was 
achieved when the IgY- Hp58 was given 1 week after infection.  There was a significant 
difference in the degree of gastritis at this point, and a higher recovery rate when 
compared to the IgY-N treated group [147].  Together, these results suggest that the IgY-
Hp58 antibody is able to prevent H. pylori infection in the mouse model.   
Salmonella 
 Salmonella enterica serovar Enteritidis (Salmonella ser. Enteritidis) and 
Salmonella enterica serovar Typhimurium (Salmonella ser. Typhimurium) are the most 
frequent serotypes of Salmonella to cause infection in humans and other animal species 
[148-150].  Salmonella is a foodborne pathogen that can cause a variety of clinical 
manifestations including  minor gastroenteritis to a more serious bacteremia that appears 
in about 8% of untreated cases [151].  Salmonella can also persist in the gastrointestinal 
tract after symptoms have resolved, causing some individuals to become chronic carriers, 
who are able to continue to spread bacteria unknowingly.  
 The first reported case of Salmonella resistant to a single antibiotic was in the 
early 1960s [152].  Since then, the chances of isolating a resistant strain has continued to 
increase.  Salmonella has many surface components, which are important for the 
bacteria’s virulence and which are ideal targets for passive antibody treatments.  Passive 
protection by egg yolk antibodies targeted against the many Salmonella surface 
  
30 
 
antibodies serve as a potential method for the control of intestinal colonization by 
Salmonella.  One such surface antigen on Salmonella ser. Enteritidis, involved in the 
pathogenesis of the bacteria, is the fimbria.  Salmonella ser. Enteritidis has been shown to 
produce three types of fimbria, referred to as SEF 14, 21, and 17 [153-155], which are 
correlated with bacterial virulence [156-159], and bacterial adherence to mucosal 
epithelium.   
To better understand the role of fimbriae in Salmonella ser. Enteritidis 
pathogenicity, and the potential for protection of egg yolk IgY antibodies, SEF-14 
specific IgY antibodies were isolated from the egg yolk of chickens immunized with 
purified SEF-14.  Western blotting confirmed the specificity of the SEF-14 IgY 
antibodies by the presence of a single immunoreactive band at 14-kDa, after the 
membrane-bound surface proteins of Salmonella ser. Enteritidis were electrophoretically 
transferred to a nitrocellulose membrane [160].  To evaluate the clinical potential of SEF-
14 IgY antibodies, mice were challenged with Salmonella ser. Enteritidis and treated with 
the SEF-14 IgY antibody.  The SEF-14 IgY antibody dose dependently increased the 
survival rate of mice treated after challenge with Salmonella ser. Enteritidis, compared to 
control mice treated with avain IgY antibody from non-immunized hens.  Mice treated 
with the highest titer of SEF-14 IgY antibody had the greatest survival rate at 77%.  The 
lower antibody titer treatment group had a 59.3% survival rate, and the control group had 
a 32% survival rate [160]. The difference in survival rate between the high antibody titer 
treatment group and the control group was significant [160].  The Salmonella ser. 
Enteritidis infected mice did not develop any overt symptoms of diarrheal disease, but in 
the mice that had the infection, the challenge bacterial strain was isolated from the liver, 
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spleen, kidney, and small intestines.  In mice that survived infection because of the 
antibody treatment, only a few harbored any bacteria in the organs listed above.   
In vitro, the SEF-14 IgY antibodies were able to reduce the adherence of 
Salmonella ser. Enteritidis to isolated murine small intestinal cells, compared to control 
antibodies.  The exact mechanism that allows the SEF-14 IgY antibody to increase 
survival is unknown; the in vitro results and lack of bacteria in the organs after antibody 
treatment, point towards the SEF-14 IgY antibodies being able to inhibit the initial 
attachment of the bacterial to cell surfaces, and, potentially, the next steps of tissue 
invasion.  The prevention of bacterial adhesion is a phenomenon that has been observed 
by others studying the effects of Salmonella specific IgY antibodies.  In vitro, IgY 
antibodies specific for the LPS of Salmonella ser. Typhimurium and Salmonella ser. 
Enteritidis have been reported to inhibit Salmonella adhesion and to prevent disease 
[161].  Chalgohoumi et al. created IgY antibodies specific for the outer membrane 
(OMP) of Salmonella ser. Typhimurium and Salmonella ser. Enteritidis.  The OMP- 
specific IgY was able to prevent Salmonella adhesion in a concentration dependent 
manner, along with inhibiting bacterial growth [162].   
 Yokoyama et al. determined the treatment potential of avian IgY antibodies 
specific for the OMP, lipopolysaccharide (LPS), and flagella (fla) of Salmonella ser. 
Enteritidis and Salmonella ser. Typhimurium[150].  The OMPs are exposed on the 
surface of the bacterial cells where they can easily interact with antibodies [163].  There 
is increasing evidence that motility facilitated by the flagella increases the probability the 
bacteria will reach a suitable site for invasion, an important part of causing an infection 
for the bacteria [164,165].  The importance of these three cellular structures in bacterial 
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pathogenesis and their surface exposure makes them ideal targets for antibody treatments.  
Avian IgY antibodies specific to the OMP, LPS, and Fla of both Salmonella ser. 
Enteritidis and Salmonella ser. Tyhimurium were made by immunization of five month 
old White leghorn chickens with OMP, LPS, or FLA from the two bacteria strains.  
Avian IgY antibodies specific to the six antigen targets were then isolated from the eggs 
of immunized chickens.  Control antibodies were isolated from the eggs of non-
immunized chickens to test the efficacy of the Salmonella specific IgY.  Mice were 
challenged with either Salmonella ser. Enteritidis or Salmonella ser. Typhimurium and 
then orally treated with either OMP-, LPS-, or Fla- IgY specific to the bacteria they were 
challgenged with.  The antibody treatment continued three times a day for three 
consecutive days.  For mice challenged with Salmonella ser. Enteritidis treatment with 
OMP-IgY resulted in 80% surivial, 47% survival with LPS-IgY, and 60% survival with 
Fla-IgY; survival for the control IgY treated mice was only 20% [150].  The difference in 
survival between the OMP-IgY treated group and the control group was significant.  
There was a similar trend in results for the mice challenged with Salmonella ser. 
Typhimurium.  The group of mice treated with OMP-IgY had 40% survival, LPS- IgY 
30% survival, and Fla- IgY 20% survival; all of the mice in the control group died [150].  
 Lee et al. developed avian IgY antibodies specific for Salmonella ser. Enteriditis 
and Salmonella ser. Typhimurium, but the aim of their research was to gain a better 
understanding of IgY antibody specificity and how the IgY antibody interacts with the 
bacteria.  The IgY antibodies used in their research was specific for whole cell bacteria.  
There was cross reactivity between the two antibodies, but ultimately both types of 
Salmonella-specific IgY antibodies were found to inhibit growth of homologous 
  
33 
 
Salmonella in liquid medium [54].  They were unable to find out the exact mechanism of 
growth inhibition, but there were structural changes to the surface of Salmonella where 
IgY bound [56].  The above mentioned research in the area of avian IgY antibody 
treatments for Salmonella has the potential to be transferred into humans to be used 
clinically to treat salmonellosis caused by food poisoning.   
Escherichia coli 
 Enterotoxigenic Escherichia coli (ETEC) causes enteric colibacillosis, severe 
watery diarrhea, in newborn (suckling) calves, and suckling as well as weaned pigs, but is 
rare and essentially non-existent as a cause of illness in other farm animals.  In humans 
ETEC is recognized as one of the most frequent causes of childhood diarrhea in 
developing countries and an important causative agent of traveler’s diarrhea [166,167].  
The similarities in prevalence and severity of disease between humans and animal cases 
of ETEC provide researchers a chance to understand human ETEC infection through the 
use of animal models.  ETEC bacteria are known to adhere to the small intestinal 
epithelium without inducing significant morphological changes and secrete enterotoxins 
that alter the functions of enterocytes by increasing secretion and reducing absorption 
[168].  Because of the importance of adhesion in the pathogenic process of ETEC, 
adhesins on the surface of fimbriae or pili are essential virulence factors.  The fimbriae of 
animal ETEC are K88, K99, K987P, Fy.Att25, F41, and F18 [169].  Potentially 
pathogenic E. coli are found in the intestinal tract and feces of many healthy animals.  
Continuous birthing and poor sanitary conditions often lead to ETEC infections in 
offspring.  Infectious ETEC on the skin and mammary glands of mothers can easily be 
ingested by offspring.   
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Treatment of ETEC infections can start with prevention of the infection all 
together, by building up the immunity of adult female cows and pigs through vaccination.  
If it is necessary to treat ETEC- infected offspring, antimicrobial treatments are often 
used.  Usually, if one offspring in the litter is infected all in the litter will have to be 
treated.  Because of which, the chances of the infection spreading through the herd are 
high.   
Avian IgY antibody treatments of ETEC infections in animals are an attractive 
option because it would reduce the use of antibiotic treatments in livestock.  An avian 
IgY antibody treatment would only persist in the animal long enough to help clear the 
infection, and would not have any long term effects in pigs or calves used as a food 
source.  Oral administration of antibodies derived from serum and colostrum and even 
monoclonal antibodies have been very successful treatments; however, it is expensive to 
obtain the large amounts of antibodies required [170].  A cost effective source of 
antibodies to treat ETEC is avian IgY antibodies, specifically egg yolk antibodies from 
immunized chickens.  There are several researchers that have used animal models of 
ETEC infection to evaluate the potential of ETEC- specific IgY antibodies.  A main 
target for these IgY antibodies are the bacteria’s adhesins most likely due to the role they 
play in bacterial pathogenesis.  Yokoyama et al. used a porcine model of ETEC infection 
to assess the treatment potential of avian IgY antibodies specific for fimbriae adhesins 
K88, K99, and K987P.  The adhesion- specific antibodies were isolated from the egg 
yolks of E.coli frimbrial immunized chickens.  In vitro the presence of anti-adhesin IgY 
prevented the adhererence of K88+, K99+, and K987P+ E.coli strains to isolated procine 
small intestine epithelial cells [171].  There was no cross-inhibition between the three 
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types of antibodies used.  Similar results were obtained in vivo in control piglets.   In 
control animals, adhering E.coli could be observed along with whole length of the small 
intestines, whereas there was no adherent E.coli along the intestinal epithelial surface of 
piglets treated with E.coli fimbriae- specific IgY [171].   
 In another experimental design, Marquardt et al. isolated polyclonal IgY 
antibodies from the egg yolks of chickens immunized with purified K88 fimbrial antigen 
from a local strain of ETEC (E.coli K88+ MB, Manitboa, Canada)[172].  The egg yolk 
antibodies were freeze dried and made into a powder to be tested in a porcine model of 
ETEC.  Piglets or neonatal pigs were challenged with K88+ MB orally and then orally 
treated with K88 MB- specific IgY antibodies or control non-specific IgY antibody 
powder at various time points post-challenge.  K88 MB- specific IgY antibody treatment 
was able to protect both neonatal and 21 day old weaned piglets from diarrhea induced by 
the challenge.  In piglets challenged and treated with K88 MB specific IgY antibodies, 
diarrhea was cured within 24 hours after treatment, whereas the piglets treated with the 
control IgY antibodies continued to have diarrhea during the entire duration of the 
experiment, resulting in 62.5% death [172].  Not only was the occurrence of diarrhea 
decreased in the neonates and piglets treated with K88 MB- specific IgY antibodies, but 
mortality was also significantly decreased.  
 Further research using the K88 MB specific IgY antibody was completed, 
studying the potential of the antibody to inhibit in vitro adhesion of K88+ E.coli to piglet 
intestinal mucus.  The effectiveness of the chicken IgY antibodies for inhibiting adhesion 
of ETEC to mucus in this study was influenced by two factors: dose of antibody, and 
concentration of ETEC.  K88 MB- specific IgY antibody, when diluted 50-100 fold, was 
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able to strongly inhibit adhesion of K88+ E.coli  at a concetnraion of 109 CFU mL-1 
(adhesion was <6%) [173].  However, if the antibody was diluted 100 times it was unable 
to prevent adhesion of E.coli.  These results correspond with the previous dose-dependent 
results of Marquardt et al. and others.  There were limits to what the K88 MB- specific 
IgY antibodies were capable of; the antibodies were unable to displace K88+ MB E.coli 
once it was already bound to the receptor in the mucus.  Also, when the IgY antibodies 
and K88+ MB E.coli were incubated together, prior to exposure to immobilized mucus, 
there was no difference in inhibition of adherence between K88 MB- specific IgY 
antibodies and control IgY antibodies [173].  For this specific application of the IgY 
antibody a prophylactic treatment approach would probably be more advantageous.   
 As was previously mentioned, ETEC is a major cause of diarrhea and death in 
neonatal calves [174-176].  The K99 pilus is one of the adherence factors found on ETEC 
isolated from neonatal calves [177-180].  As a potential alternative to current treatment 
methods for ETEC in calves, Ikemori et al. developed a pilus- specific IgY antibody 
powder[180].  Newborn colostrum-fed calves were used as the model of ETEC infection 
[180].  Calves were challenged with ETEC and then treated with either pilus- specific 
IgY antibody powder in milk, or non-specific IgY antibody powder in milk at varying 
titers.  Calves in the control group developed severe diarrhea and died on day three post 
challenge.  The opposite was true of calves treated with pilus IgY antibody powder.  The 
calves in the higher titer groups (1:800 and 1:1600) all recovered from disease; diarrhea 
was temporary, and was not accompanied by dehydration or weight loss [180].  Calves in 
the lowest antibody titer group (1:200) did experience diarrhea and weight loss.  These 
results again support the dose-dependent effects of ETEC specific IgY antibodies.  
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Rotavirus 
 Rotavirus is a key enteric pathogen in infants and young children.  Each year 
rotavirus causes millions of cases of diarrhea in children.  Almost 2 million cases will end 
up in the hospital [181], and an estimated 453,000 will result in the death of children 
under the age of 5 [182], 85% of whom live in a developing country [183].  Recently two 
vaccines have been approved for use against rotavirus.  One downfall is the vaccines’ low 
protection efficacy in children from African and Asian countries [184,185], the two 
countries that contain areas where children are at high risk for infection.  Vaccination is 
an effective method of controlling disease in developed countries because of well-
established health systems.  But, in developing countries, the outcome is much different.  
Approximately 1.76 million children die each year from gastroenteritis in developing 
countries [186], many of which are due to rotavirus [183], as indicated above.  In addition 
to vaccines against rotavirus there needs to be an easy-to-administer and cost-effective 
treatment for rotavirus.  An antibody-based passive treatment is an ideal alternative 
approach to prevent and treat rotavirus infections.   
 Several in vitro studies have proven the potential use of rotavirus specific IgY 
antibodies for treatment of rotavirus infections [187-190].  In the second human trial, 
children with proven rotavirus diarrhea were treated with anti-rotavirus IgY antibiodies 
isolated from the eggs of human rotavirus immunized hens.  There was a trend towards 
lower daily and cumulative stool output, compared to children treated with control IgY 
antibodies, however the daily and cumulative stool output difference was not significant.  
Probability of clearance of rotavirus from stool of children treated with anti-rotavirus IgY 
antibodies was significantly higher compared to the control treated children.  At day four 
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post-treatment, 74% of children treated with anti-rotavirus IgY antibodies no longer had 
detectable rotavirus in their stool, while more than 50% of children in the control IgY 
antibody treatment group still had rotavirus in their stool at this point [191].  One 
explanation for only one significant set of data in this research could be the relatively low 
dose of anti-rotavirus IgY antibodies that was used.  
 To gain insight into the dose of the efficacy of anti-rotavirus IgY antibodies, an 
animal model of rotavirus infection was used, which allowed for higher doses of anti-
rotavirus IgY antibodies to be given.  The same anti-rotavirus IgY antibodies that were 
used in the clinical trials by Sarker et al. were also used in these experiments [191].  Four 
day old mouse pups were challenged with Rhesus rotavirus.  Twenty-four hours after 
challenge, mice were treated with one of the four following doses of anti-rotavirus IgY 
antibodies: 0.01 mg/mL 0.1mg/mL, 1.0 mg/mL, or 10.0 mg/mL.  A significant difference 
in prevalence of diarrhea was reported for mice treated with doses of 1.0 or 10.0 mg/mL 
of anti-rotavirus IgY antibodies compared to control, 33% vs. 67% and 6% vs 67%, 
respectively [192].  At lower doses there was no significant difference for this parameter.  
The duration of diarrhea was reduced with anti-rotavirus IgY antibody treatment, and, 
again, larger doses caused the strongest reduction compared to the control, with a 
significant difference [192].  These results support the results of other studies: treatment 
with anti-rotavirus IgY antibody is dose dependent.  It is also possible, based on these 
results, that using a higher dose of anti-rotavirus IgY antibody in the previous clinical 
trial would have given a better outcome, especially considering the highest dose provided 
the best protection.   
Venoms  
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Envenomation, due to snakebites and other venomous animals, is an often a 
neglected public health issue affecting many individuals in underdeveloped countries, 
specifically rural and tropical Africa, Asia, and Latin America [193].  While true, 
individuals in developed countries are most at risk for envenomation during recreational 
activities.  A recent study estimates that at least 421,000 envenomings, and 20,000 deaths 
occur worldwide from snakebites each year [193], and an estimated 1.2 million scorpion 
stings occur each year, leading to 3,250 deaths [194].  Scorpion and snake venoms are a 
complex mixture of peptides, enzymes, and other factors that cause a wide variety of 
physiological reactions.  Hyaluronidase, for example, is an enzyme present in all snake 
venoms that aids in the spread of other venom components throughout the prey’s tissue 
[195].  Snake and scorpion anti-venoms are most often derived from horse sera.  Purified 
anti-venoms often contain large amounts of non-specific serum proteins that can cause 
side effects, some of which can be severe [196-198].  Side effects can range from serum 
sickness, occurring in up to 80% of all patients treated with the current North American 
rattlesnake anti-venoms [199,200], to the more severe anaphylactic reactions.  These 
reactions are in part due to the impurity of the anti-venoms and the reactivity of the anti-
venom immunoglobulins with human immune cells [199,201].  Treatment is further 
complicated by the many unknowns involved, such as the amount of venom injected by 
each poisonous animal. The lack of standardization in venom causes the amount of active 
ingredients in commercially available North American anti-venom treatments to vary.  In 
an attempt to circumvent the unwanted reactions between anti-venom immunoglobulins 
and components of the human immune system, avian IgY- specific antibodies for snake 
venom were developed.   
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Some of the first anti-venom IgY antibodies were made by immunizing chickens 
with either a mixture of Cortalid snake venom or Leiurus quinquestiratus hebraeus 
scorpion venom.  Anti-venom IgY antibody was isolated from the egg yolks of the 
immunized hens with each respective venom and affinity purified.  The neutralizing 
potential of the anti-venom IgY antibodies against both types of venoms was tested by 
mixing the anti-venom IgY antibodies with the minimum lethal dose of each venom, 
respectively, and injected into mice; the mice were then monitored for death.  All ten 
mice survived the 24 hour observation period when treated with the anti-Cortalid IgY 
antibodies and only one out of nine mice survived without the anti-venom IgY antibodies 
[202].  Results were similar for the anti- Leiurus quinquestiratus hebraeus IgY 
antibodies.  When mice were injected with Leiurus quinquestiratus hebraeus venom pre-
incubated with anti-venom IgY antibodies, seven out of eight mice survived, and only 
one out of six mice survived injection without anti-venom IgY antibodies [202].  Both the 
snake and scorpion anti-venom IgY antibodies were able to neutralize the toxins present 
in their respective venoms.   
Similarly, IgY antibodies specific for the venom of snakes within the Bothrops 
and Crotalus genera were developed through immunization of chickens with mixtures of 
venoms from snakes within each genus.  Venom- specific IgY was present in the serum 
of hens just two weeks after immunization.  Eggs were collected from the immunized 
hens and IgY isolated from the yolks of the eggs that was snake venom specific.  One 
snake venom component is phospholipase A2 (PLA2 ), which causes inflammation.  This 
is caused by liberation of archadonic acid, a precursor of prostaglandins and leukotrienes  
from the cell membranes [203].  In vitro, anti-venom IgY specific for venom from both 
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genera of snakes was able to inhibit the activity of PLA2 in a dose- dependent manner 
[204].  Both venom- specific IgY were also able to neutralize the lethal toxicity of the 
venom as assessed by an in vitro-in vivo assay [204].   
In two independent studies, Meenatchisundaram et al. studied the neutralizing 
ability of venom- specific IgY antibodies against the venom from four different snakes 
that are a common cause of human envenomation; the Naja naja (cobra), Bungarus 
caeruleus (krait), Vipera ruseeli (Russell’s viper), and Echis carinatus (Saw-scaled viper) 
[205,206].  The neutralizing ability of the venom- specific IgY antibody was assessed 
through comparison of PLA2 activity, edema formation, and procoagulant activity in anti-
venom IgY antibody treated and control treated groups of mice.  Anti-venom IgY 
antibodies made against all four venoms inhibited PLA2 activity, decreased edema 
formation, and neutralized procoagulant activity compared to controls [205,206].  These 
results support the possible neutralizing potential that these anti-venom IgY antibodies 
have in future in vivo studies and in humans.   
Others 
 Avian IgY antibodies have been developed against other targets such as the 
cytokines IL-1β and TNF.  Allergic asthma has been shown to be successfully treated 
with mammalian antibodies specific for the cytokine TNF-α [207-209].  However, further 
studies with the anti-TNF-α antibodies identified the unfavorable risks associated with 
long-term use of these treatments [210].  Another cytokine, IL-1β, is an important 
proinflammatory cytokine involved in the progression of allergic asthma, contributing to 
the formation of inflammatory responses within the airway [211].  Targeting of IL-1β by 
anti-IL-1β IgY represents an alternative treatment option for allergic asthma.   
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Wei-xu et al. used a hamster model of allergic asthma induced by ovalbumin 
(OVA) to test anti-IL-1β IgY antibodies isolated from the eggs of laying hens immunized 
with human recombinant IL-1β [212].  Allergic asthma hamsters were treated with either 
saline alone as a control, anti-IL-1β IgY antibodies, or budesonide as a positive control.  
There was decreased tissue damage in the lungs of hamsters treated with anti-IL-1β IgY 
antibodies compared to control.  There was no significant difference in the pathological 
damage between the animals treated with budesonide and those treated with anti-IL-1β 
IgY antibodies [212].  Along with preventing tissue damage, there was a significant 
decrease in the numbers of eosinophils, neutrophils, and lymphocytes along with a 
reduction in IL-1β, IL-4, IL-8, IL-13, TNF-α, TGF-β, and IgE in the peripheral blood as 
well as bronchial alveolar lavage fluid [212].   
IgY specific TNF-α antibodies have been developed for treatment of Chron’s 
disease and ulcerative colitis as a potential alternative to current treatments.  Current 
treatments include immunosuppressants, corticosteroids, and antibiotics, all of which 
come with limitations and side effects that can limit the efficacy of the treatments [213].  
TNF-α is a key early mediator in these two diseases along with many others [214].  Other 
drugs have been made against TNF-α, but they can be costly, result in multiple trips to 
the medical provider for patients, and have adverse side effects.  Anti-TNF IgY 
antibodies were developed and tested in a rodent model of inflammatory bowel (IBD) as 
a way to better treat TNF-α influenced diseases.  The anti-TNF IgY was able to 
effectively treat IBD in mice when administered both prophylactically and 
therapeutically, and was effective against both the acute and chronic phase of colitis in 
the animal model [215].   
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West Nile Virus 
Previous research in the Bradley lab at the University of North Dakota has been 
done with the immune serum from geese and purified goose IgY antibodies.  Initial 
studies were done to determine if serum from West Nile Virus (WNV) immune geese 
could prevent or treat infection.  Geese were treated with immune serum either prior to 
WNV infection or after WNV Infection.  There were approximately 10,000 geese in each 
study, which showed a marked decrease in the mortality for both groups.  More 
specifically, there was approximately a 65% reduction in mortality when used as a 
pretreatment and an approximate 62% reduction in mortality when used therapeutically 
(unpublished results Schiltz, Petell, and Bradley).  Similar results were seen with purified 
WNV- specific goose IgY antibodies. 
The effectiveness of the WNV-specific IgY antibodies were then tested during 
WNV infection in WNV-infected Golden hamsters.  WNV-specific IgY antibody 
treatment resulted in both mortality and viral titers of zero.  Comparatively, sham treated 
hamsters had a mortality rate of 100% and 65% (unpublished results Schiltz, Petell, and 
Bradley).  This research demonstrated that the goose antibodies were able to protect 
mammalian subjects against infection. 
Overview of IgY 
In summary, avian IgY antibodies are functionally similar to mammalian IgG 
homologs, but have sufficiently distinct structural characteristics.  This difference is what 
makes the use of avian IgY antibodies an attractive alternative for passive immunizations 
for mammals, specifically, in various diseases and infections in humans.  Discussed 
below is our research focused on investigating the ability of goose IgY antibodies to 
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ameliorate two human pathogens: Dengue virus type 2 and Andes virus.  Andes virus- 
specific goose IgY antibody treatments that were developed include antibodies that 
recognize unique epitopes in comparison to virus specific mammalian IgG antibodies.  
The structural differences in IgY antibodies, compared to mammalian IgG, results in IgY 
antibodies inducing less of an inflammatory response than what can be detected with 
mammalian IgG antibody therapies.  Discussed next are the general safety studies 
demonstrating the potential to utilize avian IgY antibodies in therapeutic application for 
mammalian disease. 
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CHAPTER II 
DEVELOPMENT OF GOOSE MONOCLONAL IGY ANTIBODIES FOR 
TREATMENT OF DENGUE VIRUS TYPE 2 INFECTIONS  
 
 
Introduction 
History of Dengue Virus in Humans 
The World Health Organization estimates that 50 to 200 million dengue virus 
(DENV) infections occur each year [216].  However, newer research estimates these 
numbers to be closer to 390 million cases per year, 96 million of which will lead to 
clinical manifestations of varying severity [217].  DENV is currently regarded as the 
most important arboviral disease internationally because over 50% of the world’s 
population live in areas where they are at risk of infection, and approximately 50% of 
people live in DENV endemic countries [218-222].   
DENV is a member of the Flaviviridae family of RNA viruses.  There are four 
antigentically distinct serotypes of the DENV (DENV-1, DENV-2, DENV-3, and DENV-
4) differing at the amino acid level by 25-40% [223].  Genetic studies of the four DENV 
have provided evidence that the four viruses evolved from a common ancestor that 
circulated between non-human primates and mosquitoes, approximately 500 years ago, 
with all four virus serotypes emerging separately into a human urban transmission cycle 
[224].  DENV is primarily transmitted to humans by mosquitoes from the genus Aedes, 
primarily the Aedes aegypti (A. aegypti) species, and also the Aedes albopictus species in 
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some geographical areas.  Mosquitoes become infected after taking a blood meal from an 
infected human.  After the blood meal, the virus travels into the mosquitos’ midgut and 
continues on to infect other tissues of the mosquito.  Ultimately, to infect humans, the 
virus needs to travel to the salivary glands of the mosquito and be shed in the saliva of the 
mosquito while taking a blood meal [225].  The A. aegypti mosquito is a very efficient 
vector; it has a high affinity for human blood, is adapted to urban living, and it likes to 
breed in and around houses in water containing vessels [226].   
The geographical spread of the virus is primarily in tropical and subtropical 
countries currenlty.  DENV disease awareness increased after the end of World War II, 
but the disease has a much longer history of interaction with humans dating back to 
China between 265-420 A.D. [227].  The first two modern cases of DENV infection led 
to the isolation of DENV-1 in 1943, from Japan and DENV-2 in 1945, from Hawaii 
[228].  After these two cases, epidemics of DENV began to spread to more of the tropical 
regions of the world.  This was facilitated by the spread of the mosquito at the end of 
World War II and was accelerated by urbanization and globalization; including 
increasing international travel not only of people, but also goods in which mosquitoes 
harboring the virus can survive [218].  The increased prevalence of DENV was further 
facilitated by inadequate housing, poor water systems, and improper sewer and waste 
management systems causing A. Aegypti levels to reach increasingly high densities.   
In the 1960s, there was a dramatic surge in DENV activity in many tropical 
locations throughout the world [229-232]. Increased disease severity was associated with 
these epidemics due to the overlapping spread of the four DENV serotypes, referred to as 
hyperendemicity [233-235].  Research in hyperendemic areas looking at secondary 
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heterotypic DENV infections led to the development of the antibody dependent 
enhancement (ADE) theory of pathogenesis [236].  In the 1970s, only nine countries had 
reported severe DENV cases; that number has since quadrupled [221].  This is, in part, 
due to multiple DENV serotypes circulating in the same geographic area.  Until the 
1980s, a majority of the endemic areas had only reported one or two types of DENV.  
Now all four DENV serotypes are circulating in Asia, Africa, and the Americas 
[227,237].   
As this brief history of DENV demonstrates, the spread of the virus is ultimately 
connected to the spread of its mosquito vector, which is in turn influenced by changes in 
the climate, globalization, and travel.  Moving into the future these variables will 
continue to change and so will the geographic spread of the virus into non-endemic areas 
and, as the four DENV serotypes continue to circulate, more hyperendemic areas will be 
created.  All of which will contine to increase the chances of secondary heterotypic 
infections increasing patient’s chances of severe DENV infection.   
Spread of DENV to the Americas was delayed by an A. aegypti mosquito control 
campaign initiated by the Pan American Health Organization.  The primary goal of the 
program was to control the spread of yellow fever, but also happened to control the 
spread of DENV.  This prevented the spread of DENV to the Americas for 20 years, until 
the program was discontinued in the late 1970s [218,226,238].  In the 1980s, the number 
of DENV cases began to rebound and by 1995 the A. aegypti mosquito was reintroduced 
into the Americas, and its geographic distribution spread to include Asia, and continues 
to spread to this day [222,226].  The first indigenous case of DENV in the United States 
since 1945, was reported in Brownsville, Texas in 1980.  DENV-1 was isolated from a 5-
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year-old girl that did not have a history of traveling outside of Brownsville.  An 
additional 63 DENV-1 cases were confirmed in Texas in 1980, 52 of these cases were in 
counties located near the Mexico-Texas boarder [239].  More recently in 2005, 
autochthonous DHF was reported in a woman in Texas, and 25 additional cases of DENV 
infections were reported in Brownsville, Texas, of which at least three were locally 
acquired [240].  Between 2009 and 2012, a total of 103 autochthonous DENV cases were 
reported in Florida [241,242].  Testing of mosquitoes in the area detected the presence of 
DENV-1 in A. aegypti mosquitoes [243].  Previously, people living in the United States 
only have to be concerned about DENV infections, when traveling to areas where the 
virus was endemic, but now the mosquito vector has spread such that infections of DENV 
can be acquired within the continental United States. 
DENV Structure 
DENV is a small, enveloped virus with a single-stranded, positive-polarity RNA 
genome of 10.7kb [244].  The 10.7kb genome is translated as a single polyprotein and 
then cleaved into three structural proteins (capsid [C], premembrane/membrane [prM/M], 
and envelope [E]) and seven nonstructural (NS) proteins, (NS1, 2A, 2B, 3, 4A, 4B and 5) 
by host and viral proteases [245-247].  DENV primarily infects cells of the monocyte-
macrophage lineage, liver, and endothelial cell linings of blood vessels [248-250].  The 
first cells to be infected with DENV are typically tissue resident Langerhans cells in the 
skin, due to their close proximity to the mosquito bite and virus entering the host.  E 
protein on the surface of the virus interacts with receptors on the host cell surface.  It is 
unknown which receptor(s) on host cells facilitate the entry of DENV; one possible 
receptor is DC-SIGN [251].  Once in the cell, the acidic environment of the endosome 
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triggers a structural change in the E protein, which results in fusion of the viral, and cell 
membranes [252,253].  The virus nucleocapsid is released into the cell cytoplasm, the 
viral RNA and the capsid protein can then dissociate.  Initially the viral RNA genome is 
translated into a single polyprotein that is then co- and post-translationally cleaved into 
the appropriate proteins.  During translation, structural proteins are translocated and 
anchored in the ER by various signal sequences and membrane anchor domains.  After 
appropriate cleavages the capsid protein and viral RNA localize in the cytoplasm, the 
capsid protein remains associated with ER, and the prM and E proteins form 
heterodimers on the lumenal side of the ER [254-256].  After the initial round of 
translation, viral replication begins.   
Replication is carried out by the NS5 protein, which functions as a RNA 
dependent, RNA polymerase along with help from a viral helicase and other unidentified 
proteins [257].  At the start of replication the positive stranded RNA genome is first 
transcribed into a complementary negative-strand RNA, this results in a double-stranded 
RNA (dsRNA) intermediate [258].  The negative strand of the dsRNA continues on to 
serve as the template for any positive-strand RNA that is made.  Viral RNA synthesis is 
asymmetric, meaning ten times more positive-strand RNA is made than negative-strand.  
Positive-strand RNA can serve as the viral genome or enter another translation cycle, 
while all negative-strand RNA exists only as part of the dsRNA intermediate [259].  Viral 
components then come together for assembly of viral particles.  Initially, immature virus 
particles are assembled in the lumen of the ER.  These viral particles are immature 
because they are unable to facilitate host-cell membrane fusion due to the fact that the 
surface of the virus has an icosahedral arrangement with 60 trimeric spikes, each made up 
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of prM heterodimer with the prM protein positioned at the tip of each E protein trimer 
[246,260-262].  The immature virus particles are transported through the trans-Golgi 
network where they will mature into infectious virions.  In the low pH of the trans-Golgi 
network the pr peptide is cleaved from the M protein by the host protease furin.  The 60 
timers of prM-E then dissociate to reform as 90 anti-parallel E protein homodimers which 
lie flat on the surface of the mature virion [245,252,263,264].  The mature virion is then 
released from the host cell by exocytosis [252].   
DENV Immunopathogenesis 
The pathogenesis of DENV relies on the interplay between the virus and host 
factors that result in a variety of clinical manifestations.  Clinical disease caused by 
DENV infections can range from an asymptomatic infection in some individuals, to mild 
dengue fever (DF), or the more severe dengue hemorrhagic fever (DHF)/dengue shock 
syndrome (DSS).  Most primary DENV infections in patients over the age of one year old 
manifest as either asymptomatic or DF.  During the primary DENV infection, lifelong 
immunity is established in the individual against the infecting DENV serotype [265,266].  
During subsequent infections with heterotypic DENV serotypes individuals are at a 15-80 
times greater risk for developing the more severe DHF; 90% of all cases of DHF occur 
during secondary heterotypic DENV infections [267]. The increase in severity of the 
secondary infection is dependent, in part, on ADE [227,268-270].   
ADE is caused by cross-reactive or sub-neutralizing antibodies binding to the 
virus, forming immune complexes.  The complexes utilize their Fcγ receptor (FcγR) 
binding to bind cells, facilitating virus entry into cells and triggering inflammation and 
associated shock-like symptoms [267,269,271,272].  There are a small number of severe 
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DHF cases in primary DENV infections, most of which are often transmitted to infants 
born to DENV-immune mothers [273].  It is thought that children born to DENV-immune 
mothers are protected against DENV by antibodies transferred from the mother during 
the first three to four months after birth.  Following those first few months, the 
neutralizing ability of the antibodies declines and become non-neutralizing, which 
actually enhancing the chances of infection until about the age of one.  At age one, the 
maternal antibody levels are cleared from the child and no longer pose a risk [227,274-
276].   
The majority of DENV infections are asymptomatic, but for those who develop a 
symptomatic infection, the incubation period can range from three to fourteen days, and 
typically span four to seven days [265,277-280].  The majority of individuals with 
symptomatic DENV infections develop DF, which most commonly presents as a sudden 
onset of fever lasting two to seven days.  Accompanying the fever is a severe headache, 
pain behind the eyes, generalized myalgia and arthralgia, rash, anorexia, abdominal pain, 
and nausea [281,282].  DF is typically milder in younger children compared with older 
children and adults [268,273,280].  Common laboratory abnormalities seen in DF patients 
are leukopenia, thrombocytopenia, and elevation in serum transaminases [273,283-285].  
Most patients recover from DF fully without any lasting chronic symptoms or 
complications within a week after the onset of disease [286].  Some atypical clinical 
features of DENV infections include encephalitis, myocarditis, hepatitis, pancreatitis, and 
acute respiratory distress syndrome.  The atypical manifestations are most likely due to 
disease pathology at different endothelial surfaces [287-291].  The more severe forms of 
DENV infection, DHF and DSS, begin with the same clinical symptoms as DF, but then 
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progress to include hemorrhaging and increased vascular permeability due to the viral 
infection.  Viremia in DHF/DSS is generally 10-to-100 fold higher than in DF [292].  As 
was noted above, DHF/DSS is most often seen in secondary heterotypic DENV 
infections and is therefore more common in areas where all four DENV serotypes are 
circulating [221].  Four to five days after the onset of DF-like symptoms, DHF patients 
usually show a decline in their fever and shortly thereafter the patient’s condition begins 
to deteriorate, starting with a narrowing of the pulse pressure.  Patients then typically 
become hypotensive due to plasma leakage, and there may hemorrhagic manifestation 
[266].  The DSS stage is entered at the onset of increased vascular permeability, resulting 
in a loss of plasma fluids into the interstitial spaces, so much so that cardiac output is 
compromised resulting in hypovolemic shock [293].  The shock stage is short in duration 
but life threatening and within 24 hours patients will either survive or succumb to the 
infection [294].   
The World Health Organization (WHO) categorizes DHF/DSS into four grades 
based on severity, from the less severe (grade 1) to the more severe (grade 4).  If patients 
progress to DSS they are categorize in either grades 3 or 4 [216].  Unfortunately, only 
supportive treatment is available for DF, DHF and DSS patients.  Currently there are no 
antiviral treatments available for DENV in general, and vaccine development has been 
challenged by the requirement to protect against the four serotypes to prevent ADE.  
Presently, the only way to prevent DENV infections is to control to the mosquito vector.   
Immune Response to DENV 
Humoral and cellular immunity both play a role in the protection and clearance of 
DENV infections.  During a primary DENV infections, these two branches of the 
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immune response are able limit most infections of milder DF, and allow for the 
development of immunological memory that can protect the individual against 
subsequent infections with that DENV serotype.  In contrast, during secondary 
heterotypic DENV infections the memory immune cells from the previous infection 
generate a less than ideal immune response against the virus.  This enhances the infection 
and often times causes a more severe DHF/DSS reaction.   
During a primary infection, DENV enters the skin and is processed by 
Langerhans cells and immature dendritic cells (iDC) present in the dermis.  The 
Langerhans cells, and other immune cells in the area, are activated to release IFN-γ and 
other cytokines.  The iDCs then travel to the lymph node where they mature and play a 
part in initiating the cellular and humoral immune responses through interactions with 
CD4+ and CD8+ T-cells.  During a primary DENV infection, cytolytic effects of CD8+  T-
cells are important in the host’s defense against the virus [295].  The T-cells also produce 
IFN-γ and TNF-α, which augment the anti-viral response.  CD4+ T-cells can go on to 
activate B-cells to produce IgM followed by IgG, predominantly subclasses IgG1 and 
IgG3 [296].  At this stage of infection, the humoral response may also play a role in 
controlling the infection.  IgM antibodies are typically the first antibody isotype present 
after infection, detectable three to five days after illness in 50% of patients, increasing to 
93-99% of patients after six to ten days of illness [227].  The DENV-specific IgM levels 
usually peak two weeks after the onset of fever and then decline over the next two to 
three months [221,297-299]; virus specific IgG is detectable in patients after the first 
week of illness and then continues to increase [227].  After the virus leaves the skin it can 
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travel through the blood to infect other tissues and tissue macrophages, especially those 
in the liver and spleen [250].   
In a secondary heterotypic DENV infection, patients are at an increased risk of 
developing DHF/DSS; pre-existing immunity from a previous DENV infection, age, and 
time between infections, are each primary risk factors.  The exact pathogenesis of 
DHF/DSS is still poorly understood, but there are two known contributing immune 
factors: ADE [227,268-270,300] and original antigenic sin (OAS) [301,302].   
In ADE antibodies from the primary DENV infection remain active, but are non- 
or sub-neutralizing against the DENV serotype causing the current infection.  These 
antibodies bind to the virus, forming antibody-virus complexes that gain access into FcγR 
bearing cells via the Fc portion of the antibody [266,267,269,271,272].  This increases 
the number of DCs and monocytes/macrophages that are infected in the blood of 
DHF/DSS patients increasing the viral load in patients, immune activation of the cells, 
and cytokine release [292].  Antibody-antigen complexes also have the potential to 
activate the complement pathway, leading to temporal plasma leakage [303,304]. There is 
a 10- to 100-fold greater level of virus in the blood of DHF/DSS patients compared to DF 
patients [292].   
OAS is the second proposed contributing factor to DHF/DSS.  During a 
secondary heterotypic DENV infection, memory T-cells from the previous DENV 
infection are re-activated.  As a result the T-cell response is directed against the DENV 
serotype from the primary infection rather than developing a response specific to the 
current DENV serotype causing the infection, further increasing the viral load due to 
decreased viral clearance.  There is also an increased production of cytokines by these T-
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cells and other uninfected bystander cells along with an increase in the apoptosis of 
bystander cells, which can lead to heptatic injury.  Additionally, there are autoimmune 
factors involved in the pathogenesis of DENV.  Antibodies to NS1 have been reported to 
be cross-reactive with human platelets and endothelial cells.  Antibodies against the E 
protein are also cross-reactive with human plasminogen [305].  The interaction of these 
cross-reactive antibodies with their targets within the host can further augment the 
symptoms of DHF/DSS [304,306].   
Overall in DHF/DSS there is an increase in the number of virally infected cells 
due to both ADE and OAS, as well as an increased production of cytokines, some of 
which are proinflammatory.  These proinflammatory cytokines, especially TNF-α [307-
309], IL-6 [250,308], IL-8 [250] and IL-12 [250], interact with endothelial cells creating 
leaky junctions, increasing the vascular permeability, and deficiencies in coagulation, 
leading to the associated symptoms of DHF/DSS [250,309-311].   
The pivotal role that antibodies play in either clearing or enhancing DENV 
infections makes identifying neutralizing epitopes of the virus a key area of research.  
Just six days after the bite from a DENV-infected mosquito, the body can begin to 
develop a humoral immune response against the virus [266,296,312-315].  Most 
protective antibodies, typical of this humoral immune response, are directed at the three 
domains (DI, DII, and DIII) of the structural E protein [316-319].  The central domain, 
DI, contains nonneturalizing epitopes and is thought to be involved in the low-pH-
triggered conformation changes [320].  Neutralizing epitopes are found within the highly 
conserved fusion loop in DII, which interacts with the host cell membrane during fusion 
[320-323], and the lateral ride or fusion loop in DIII [247,271,319,324-326].  It has been 
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found that for other flaviviruses, protective antibodies also recognize some of the NS 
proteins (NS3 and NS5), and the prM protein [316,318,327].  However, the antibody 
response against the NS proteins is weak, especially in primary DENV infections 
[318,328].   
Research completed with a common experimental strain of DENV-2 has 
identified three major epitopes that are recognized by mammalian neutralizing antibodies: 
the lateral ridge in DIII, the fusion loop in DII, and the less common A strand in DII of 
the E protein [247,329].  Despite the protective potential of passive antibody treatments 
for DENV infection, their use is hindered by the threat of ADE.  It has previously been 
shown that genetically modified mammalian IgG antibodies that bind DENV-2, but lack 
the ability to bind FcγRs, work as prophylactic and therapeutic treatments against DENV-
2 infections without interference from ADE [270].  The difference in the Fc portion of 
avian antibodies compared to mammalian antibodies makes avian monoclonal antibodies 
a possible treatment for DENV infections.  Avian antibodies have the potential to avoid 
ADE and allow successful passive antibody treatment of DENV infections.   
Goose Monoclonal IgY Antibodies as a Treatment Against DENV-2 Infections 
The aim of this project was to develop a goose monoclonal IgY antibody that 
could be used to as a treatment against DENV-2 infections.  Avian monoclonal IgY 
antibodies are a logical treatment option for DENV-2 infections because of their potential 
to overcome the shortcomings of current therapeutic antibodies, including the HAMA 
response and other adverse reactions because of the structural difference in the Fc portion 
of mammalian IgG and avian IgY antibodies [44,46].  This is a favorable treatment 
option over polyclonal antibodies because of the homogenous and consistent response 
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that is generated.  Once the hybridomas are developed, the monoclonal IgY antibodies 
become a renewable resource.  Using monoclonal IgY antibodies would also provide the 
protection while preventing ADE and other complications caused by DENV-antibody 
complex uptake.   
In this study we show for the first time attempts to use traditional hybridoma 
techniques to develop a goose monoclonal IgY antibody.   
 
Materials and Methods 
Geese 
 Geese were vaccinated against Pasteurella multocida types 1, 4, and 3x4 (the 
causative agent of fowl cholera) at 12-18 weeks of age, and again four to six weeks later 
using the AviPro 108 FC4 vaccine (Lohmann Animal Health, Winslow, Maine, USA).  
Blood was collected from the vaccinated geese and used as a source of immune B-cells.  
Geese were immunized subcutaneously with DENV-2 antigen (Microbix, Mississauga, 
ON, Canada) derived from the parental DENV-2 strain PLO46 Taiwanese isolate [330].  
Vaccinations took place on day zero with a 1:1 mixture of DENV-2 antigen with 
complete Freund’s adjuvant.  A booster vaccination was administered two and four 
weeks later with a 1:1 mixture of the DENV-2 antigen with incomplete Freund’s 
adjuvant.  Six weeks later, blood was collected from the immunized geese.  Geese were 
housed in either an isolation unit (ISO) or specific pathogen free unit (SPF) for the 
duration of the experiment.   
Hybridoma Techniques 
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 Blood from vaccinated geese was separated using a ficoll-paque gradient.  The 
lymphocyte layer was isolated from the gradient and used as a source of immune B-cells.  
Cells were then washed, and viability was determined in a hemocytometer using 0.2% 
trypan blue.  The goose immune B-cells were mixed with the Sp2/0-Ag14 mouse 
myeloma cell line under fusion conditions with 50% polyethylene glycol (Polysciences, 
Inc., Warringto, PA, USA).   
To select for B-cell fusions, B-cells were cultured at 2.5x106 cells/mL in 96-well 
plates in complete DMEM-20/HEPES/Pyruvate/HAT media (advanced DMEM), 
supplemented with 2mM L-glutamine, 50μM 2-ME (Sigma, MO, USA), 100 U/mL 
penicillin 100μg/mL, streptomycin sulfate, 20% fetal bovine serum (FBS) (Gibco BRL, 
Grand Island, NY, USA), 10mM HEPES 1mM sodium pyruvate (Cellgro, Mediatech 
Inc., VA, USA), and 10x HAT (Cellgro, Meditech Inc, Va, USA) at 37º C in 5% 
humidified CO2 for two weeks.  Before switching to DMEM/HEPES/Pyruvate/HT 
containing media (advanced DMEM, supplemented with 2mM L-glutamine, 50μM 2-ME 
(Sigma, MO, USA), 100U/mL penicillin 100μg/mL, streptomycin sulfate, 20% fetal 
bovine serum (FBS) (Gibco BRL, Grand Island, NY, USA), 10mM HEPES 1mM sodium 
pyruvate (Cellgro, Mediatech Inc., VA, USA, and 1x HT (Gibco, Grand Island, NY, 
USA)), and then on day 15 and for the remainder of the experiment, cells were cultured 
in DMEM/HEPES/Pyruvate media (advanced DMEM, supplemented with 2mM L-
glutamine, 50μM 2-ME (Sigma, MO, USA), 100U/mL penicillin 100μg/mL, 
streptomycin sulfate, 20% fetal bovine serum (FBS) (Gibco BRL, Grand Island, NY, 
USA), 10mM HEPES 1mM sodium pyruvate (Cellgro, Mediatech Inc., VA, USA).   
  
59 
 
After approximately three weeks, culture supernatants were screened for fowl 
cholera- or DENV-2- specific goose antibodies.  Hybridomas were ready to screen when: 
1) there was 10-25% confluence in wells with cell growth, and 2) when the wells with 
dense growth turned yellow within two days after feeding due to waste production.   
Hybridoma Screening 
 Culture supernatants from wells containing potential hybridomas were screened 
for either fowl cholera- or DENV-2- specific goose antibodies using an ELISA.  Briefly, 
one hundred microliters of DENV-2 antigen (Microbix, Mississauga, ON, Canada), or 
fowl cholera vaccine was used as a capture antigen to coat Costar EIA/RIA96-well plates 
(Corning, New York, NY, USA) and then incubated overnight at 4ºC.  Plates were 
washed five times with PBS/0.5% Tween-20 (PBST), and then blocked by adding 200μL 
1% BSA in 1xPBS to each well after incubation for two hours at room temperature (RT).  
Plates were washed five times with PBST before samples were added.  Culture 
supernatants samples were diluted 1:3.  Serum from fowl cholera or DENV-2 immunized 
geese was used as a positive control, diluted 1:50.  One hundred microliters of samples 
and controls were loaded into wells in triplicate.  Samples were incubated overnight at 
4ºC and washed five times with PBST.  DENV-2 specific IgY was detected by incubation 
with either an HRP-conjugated donkey anti-chicken IgY (Gallus Immunotech, Fergus, 
ON, Canada) or AP-conjugated rabbit anti-chicken IgY (Sigma, MO, USA), for one hour 
at 37ºC.  The plates were washed five times with PBST and the reaction was visualized 
with TMB substrate (Thermo Scientific, Rockford, IL, USA) or pNPP substrate (Thermo 
Scientific, Rockford, IL, USA).  The colorimetric change of each well was determined at 
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an optical density of 450nm or 405nm on a Thermomax Microplate Reader (Molecular 
Devices, Sunnyvale, CA, USA).   
Cloning by Limiting Dilution 
 Candidate hybridomas were prepared at a concentration of 50 viable cells/well 
and five viable cells/well in 10mL of cloning and expansion medium, 
DMEM/HEPES/Pyruvate media supplemented with cloning media (advanced DMEM), 
supplemented with 2mM L-glutamine, 50μM 2-ME (Sigma, MO, USA), 100 U/mL 
penicillin 100μg/mL, streptomycin sulfate, 20% fetal bovine serum (FBS) (Gibco BRL, 
Grand Island, NY, USA), 10mM HEPES 1mM sodium pyruvate (Cellgro, Mediatech 
Inc., VA, USA), 5% BriClone (QED Bioscience Inc. San Diego, CA, USA).  96-well 
plates were then seeded with the cell suspensions at 200μL per well and cells were 
cultured at 37º C in 5% humidified CO2.  Wells containing hybridoma clones were 
screened for production of fowl cholera- or DENV-2- specific IgY antibodies using the 
same ELISA screening method.   
 
Results 
Modification of Mammalian Hybridoma Techniques using Fowl Cholera 
 Preliminary work was done to first demonstrate the modification of mammalian 
techniques to the avian system using geese vaccinated against fowl cholera caused by the 
bacteria Pasturella multocida (P. multocida).  Fowl cholera can infect both wild and 
domestic birds causing either an acute or chronic infection, resulting in high morbidity 
and mortality that spreads easily from bird-to-to bird within flocks.  Asymptomatic and 
chronic carriers play a key role in disease transmission.  Disease prevention is important 
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especially for commercial farmers to prevent fowl cholera from wiping out their flocks.  
Blood was used as an alternative source of immune B-cells.  Blood was collected from 
geese vaccinated against fowl cholera.  The lymphocyte layer was isolated from goose 
blood separated using a ficoll-paque gradient.  The purified goose B-cells were fused 
with mouse myeloma cells (Sp2/0-Ag14) at a 1:1 ratio in the presence of 50% PEG and 
grown in HAT containing media to select for the growth of only B-cell-myeloma cell 
fusions.  After three weeks of growth, culture supernatants were screened for the 
production of anti-cholera IgY antibodies using an ELISA.   
 Supernatant from sixty potential hydridoma containing tissue culture plate wells 
was screened.  Anti-fowl cholera IgY antibody levels in culture supernatant were 
compared to the anti-cholera IgY antibody levels found in serum from fowl cholera 
vaccinated geese; antibodies found in the serum were used as a positive control.  Results 
for 41 a hybdridoma that did not produce any fowl cholera- specific IgY antibodies are 
inducled for comparison.  Of the sixty wells screened, six contained high responding 
hydridomas, 6, 16, 18, 21, 22, and 24 (Fig 1).  These hybridomas produced higher 
amounts of anti-cholera IgY antibodies than the three low responder hybdriomas 52, 59, 
and 60 (Fig 1).  These results demonstrated that it is possible to make goose B-cell 
hybdridoma using mammalian techniques and supports the feasibility of the development 
of a goose monoclonal IgY antibody.  Focus was then shifted to making goose 
monoclonal IgY antibodies against the relevant human pathogen DENV-2.
  
62 
 
 
Figure 1.  Presence of fowl cholera specific IgY antibodies as determined by ELISA.  
Culture supernatants from potential hybridoma containing tissue culture wells were 
collected approximately three weeks after fusion and analyzed for the presence of fowl 
cholera specific IgY antibodies by ELISA.  Serum from vaccinated geese was used for 
comparison.  Readings were taken at an optical density (OD) of 450nm.  Each sample 
was run in triplicate and the bars represent standard error.   
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Development of DENV-2 Specific Goose Monoclonal IgY Antibodies  
 This study focused on the development of a goose monoclonal IgY antibody using 
the modified mammalian hybridoma technique developed using fowl cholera.  Female 
geese housed in either an ISO or SPF unit were vaccinated with a DENV-2 antigen in 
adjuvant on experiment day zero, and then booster vaccinated two and four weeks later.  
Eggs and blood were collected from the vaccinated geese weekly starting two weeks into 
the experiment.  The lymphocyte layer containing immune B-cells was isolated from 
blood collected from DENV-2 antigen vaccinated geese using a ficoll-paque gradient.  
The immune goose B-cells were fused with the Sp2/0-Ag14 mouse myeloma cell line at a 
1:1 ratio to form hybridomas.  This process was repeated several times as new blood 
samples were received.  After approximately three weeks of incubation in various types 
of media, culture supernatants from wells containing potential hybridomas were screened 
using an ELISA.   
 Twenty-nine potential hybridoma containing wells were screened for the presence 
of DENV-2 specific IgY antibodies.  Serum from the immunized geese showed 
detectable amounts of DENV-2 specific IgY antibodies and was used as a positive 
control in the ELISAs (Fig 2).  Of the 29 wells screened, six were producing high levels 
of DENV-2 specific IgY antibodies: those in wells C1, E6, E8, F2, H3, and D6.  Results 
for E1, a hybridoma that did not produce any DENV-2 specific IgY antibodies, are 
included for comparison.  The DENV-2 specific IgY antibody levels produced from the 
hybdridoma present in well C1 were higher than that of the positive control goose sera 
(Fig 2).  The hybdriomas present in wells C1, E6, E8, F2, H3, and D6 were subcloned by 
limiting dilution in cloning/expansion medium containing a subcloning media 
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supplement.  After limiting dilution, culture supernatants were again screened for the 
presence of DENV-2 specific IgY antibodies.  There were no DENV-2 specific IgY 
antibodies detected in any of the culture supernatants from wells containing the 
subcloned hybdriomas or the parent hybdriomas compared to controls (data not shown).  
This suggests the fusion between the goose B-cells and mouse myeloma cells cannot be 
maintained over a long period of time.   
 IgY antibodies were also isolated from the yolks of eggs collected from 
vaccinated geese and an ELISA was completed to confirm the presence of DENV-2 
specific IgY antibodies and to determine the titers of the antibodies present in the eggs.  
Because IgY is transferred from the serum of the goose to the egg yolk to protect the 
developing embryo, egg yolk IgY antibody titers are also indicative of serum titers.  The 
average titer of IgY antibody from the eggs of geese housed specifically in the SPF 
facility was 1:732,459, with the highest being 1:6,400,000 (Fig 3).  For the eggs of geese 
from the ISO unit, the average titers was 1:877,465, with the highest titer being 1:3, 
200,000 (Fig 3).  There results indicate that an active immune response was formed 
against the DENV-2 antigen by the geese, and that DENV-2 specific immune B-cells are 
present in the blood of vaccinated geese. 
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Figure 2.  DENV-2 specific IgY antibodies were initially present in culture supernatants 
from candidate hybridomas.  Culture supernatant samples were collected from candidate 
hybridoma containing wells approximately three weeks after fusion with myeloma cells.  
The presence of antigen specific DENV-2 antibodies was detected using an ELISA read 
at an OD of 450nm.  Serum from vaccinated geese was used as a positive control for 
comparison.  Each sample was run in triplicate, and bars represent standard deviation.  
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Figure 3.  DENV-2 specific IgY antibody is present in the yolks of eggs collected from 
immunized geese. Eggs were collected from vaccinated geese housed in both the ISO unit 
(closed circle) (n=71) and SPF unit (open circle) (n=61), respectively.  A sample was 
collected from each egg after processing for IgY antibody isolation.  DENV-2 specific 
IgY antibody titers present in the eggs were determined using an ELISA.  Arrows 
indicate booster immunizations.  Data presented is a representative mean and bars 
indicate standard error.   
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Discussion 
 We show in this study, for the first time, that is possible to develop short-lasting 
hybdridoma fusions between goose B-cells and mouse myeloma Sp2/0-Ag14 cells 
capable of producing antigen- specific monoclonal avian IgY antibodies.  Previously, 
monoclonal IgY antibodies have been developed using murine/avian chimeric constructs 
and phage display techniques [331,332].  However. chimeric antibodies utilizing the 
constant region of an avian IgY antibody, and the variable region of mammalian IgG, are 
still limited to the antigens they can recognize by the mammalian variable region, which 
is responsible for binding the antigen [59].  These antibodies would not be useful against 
targets that are highly conserved in the mammalian system, which is why the ability to 
make completely avian monoclonal antibodies is advantageous.  In the present study, it 
has been shown that, at least the initial stages of hybridoma, development is possible 
using traditional mammalian hybdridoma techniques, fusing goose B-cells and mouse 
myeloma cells.   
 Vaccination against fowl cholera and immunization with DENV-2 antigens 
induced strong humoral responses in the geese, as shown by the amount of antigen 
specific IgY antibody detected in the serum of immunized geese (Fig 1 and Fig 2).  This 
coincides with research that emphasizes the role of antibodies in the immune response to 
DENV-2 infections [296].  Dengue specific IgG antibody is present in the serum of 
DENV-2 infected patients after just a week of illness [227,296].  Similarly, DENV-2 
antigen specific titers were maintained within eggs at least six weeks into the experiment, 
and peaked with titers well into the millions (Fig 3).  The high antibody titers in the eggs 
and the positive response by the serum from DENV-2 geese are both evidence for the 
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development of a humoral response by these geese against the DENV-2 antigen.  The 
development of a humoral response also means antigen- specific antibody producing B-
cells are present in the blood of the vaccinated geese.  Therefore, a lack of immune B-
cells was not the main contributing factor to the problems with hybridoma development.  
These results also support the general assumption that birds develop a robust immune 
responses against a diverse array of antigens.   
The fowl cholera vaccine used in these experiments, was an inactivated vaccine 
formulation containing inactivated P. multocida in an oil-based emulsion.  We report here 
that vaccination induced high serum anti-fowl cholera IgY antibody production.  This is 
in agreement with studies completed in turkeys infected with an avirulent fowl cholera 
vaccine, in which systemic antibody titers were induced [333,334].  The efficacy of such 
vaccine formulations have also been studied in chickens and have been shown to be 
effective in protection against bacteria challenge [335,336].  These results, along with 
those of others, support the presence of fowl cholera specific immune B-cells in the blood 
of vaccinated geese and confirms the successful development of antibody producing 
hybdriomas between goose immune B-cells and mouse myeloma cells.   
There was a reasonable amount of variability in the amount of fowl cholera- 
specific goose monoclonal IgY antibodies detected in the cultured supernatants from the 
various hybdriomas.  This varability in results could have been due to an uneven coating 
of the ELISA plates.  ELISA plates used to detect the fowl cholera specific IgY 
antibodies were coated with a vaccine in an oil-based emulsion, the extra material present 
in this preparation could have caused an uneven coating of the plate with the target 
antigen and led to variability in results.   
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 Chicken monoclonal antibodies have been produced using hydbridoma 
technology: through fusion of immune B-cells with either a chicken B-cell line, or 
chicken non-secreting mouse myeloma cell line, both of which are not commercially 
available [337-343].  These chicken monoclonal antibodies were developed against 
various antigens, including prions and protozoa.  Antigen specific IgY antibody 
production by chickens was induced using a similar method as in these currently 
described experiments [339,341,342].  Chickens were immunized with a given antigen 
and then fusion experiments were completed with the chicken cell lines.  One difference 
between their protocol and that of this study was the use of immune spleen cells from the 
immunized chickens as a source of antigen specific B-cells for fusion with the chicken 
cell lines.  In this study immune B-cells from the blood were fused with the mouse 
myeloma cells.  Monoclonal IgY antibodies made by fusing immune spleen cells with 
chicken non-secreting myeloma cells lines were reported to continue to produce high 
levels of antigen- specific IgY antibody for over six months even after subcloning [340].  
It is possible that the chicken myeloma cells would work as a cell fusion partner for the 
goose B-cells and lead to successful hybdriomas, but the difference in antibodies 
produced by anseriformes birds (geese) and galiformes birds (chickens), mainly the lack 
of IgY(ΔFc) production by chickens when compared to geese, could impact fusion 
viability.  Using an alternative source of goose immune B-cells could have been one way 
to increase the fusion strength between the goose B-cells and mouse myeloma cells.  
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CHAPTER III 
CHARACTERIZATION OF ANDES VIRUS SPECIFIC IGY ANTIBODIES 
FROM DNA VACCINATED GEESE FUR USE AS AN ANTI-VIRAL 
TREATMENT 
 
Introduction 
History of Andes Virus in Humans 
 The Andes virus (ANDV) is a New World Hantavirus from the genus Hantavirus 
within the Bunyavirdae family of viruses.  The 21 hantaviruses that cause disease in 
humans are distributed worldwide, and can be differentiated based on phylogenetic 
origins into Old World and New World hantaviruses.  Old World hantaviruses can be 
found in Asia and Europe, and New world hantaviruses can be found in North, Central 
and South America.  Along with differences in location, New and Old World 
hantaviruses also differ in the type of syndrome they cause.  Old World hantaviruses 
cause a hemorrhagic fever with renal syndrome (HFRS) while New World Hantaviruses 
cause hantavirus pulmonary syndrome (HPS).   
In the past century there have been two major disease outbreaks that led to the 
discovery of both the Old and New World hantaviruses.  The first outbreak occurred 
during the Korean War in the early 1950s, during which over 3,000 military troops fell ill 
with a hemorrhagic fever, later determined to be HFRS [344,345].  In 1978, the Hantaan 
virus, an Old World hantavirus, was identified as the causative agent of the troops cases 
of HFRS [346].  The second outbreak occurred in the Four Corners region of the United 
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States in 1993.  Adults in this region were afflicted with a severe respiratory illness 
caused by a virus, later identified as HPS caused by the Sin Nombre virus (SNV), a New 
World hantavirus [347].  In 1995, a hantavirus similar to SNV was identified in South 
America, the ANDV.  ANDV was first reported and identified as the causative agent of a 
HPS outbreak in Argentina [348-350].  Since then additional outbreaks of HPS caused by 
ANDV have occurred throughout South and Central American, including Brazil, Chile, 
and Uruguay [351,352].  ANDV continues to be the only hantavirus known to cause HPS 
in Chile.   
Within the Bunyaviridae family hantaviruses are unique in that they are mainly 
transmitted to humans by the inhalation of virus particles that become aerosolized from 
the excrement or bodily fluids (urine, feces, or saliva) of chronically infected rodents 
[353].  Infection of the reservoir rodents is primarily subclinical.  In nature, transmission 
of the virus between reservoir and non-reservoir rodents is thought to occur primarily 
through aggressive behavior and exposure to saliva and excreta [354,355].  It has also 
been shown that rodents can transmit virus through infected excrement within rodent 
nests [356-358].  Hantaviruses follow the single virus/single host rule of natural 
reservoirs, meaning each hantavirus has a specific rodent species as a natural host 
[345,359,360].  As a result, the geographical distribution of different hantavirus strains is 
determined by the distribution of their rodent reservoir.  The primary natural reservoir for 
the ANDV in Chile is the Oligoryzomys longicaudatus, the long- tailed pygmy rat [361].   
Along with normal rodent transmission, ANDV is the only hantavirus that is 
known to be transmitted person-to-person [352,362,363].  Person-to-person transmission 
occurs primarily within families or between sexual partners due to the likelihood of close 
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contact with the infected person [364].  This type of transmission is more likely to occur 
during the prodromic phase of disease.  This is an early stage of disease that can range 
from 12 to 27 days [363,365].  Other examples of transmission are by bites from rodents 
and blood transfusions [351,366].  In Chile, more than half of the HPS cases are 
associated with outdoor occupations such as forestry or agriculture [367,368].  Seasonal 
HPS cases in Chile during November to April are typically a result of outdoor 
recreational activities (20-35% of reported cases) during which time individuals are more 
likely to come in contact with infected rodents [367,368].  HPS outbreaks can be 
unpredictable, localized, and sporadic due to fluctuations in the rodent reservoirs and 
changes in the prevalence of the hantaviruses in the reservoirs.  In the Americas, the 
emergence of hantaviruses has been linked to precipitation [369,370].  Studies suggest 
that precipitation can indirectly increase reservoir species populations and therefore 
hantavirus prevalence [369,371,372]. 
ANDV Structure and Life Cycle  
 ANDV is an enveloped virus with a negative sense trisegmented single-stranded 
RNA genome.  The three genome segments S, M, and L encode for three different 
proteins: the nucleocapsid (N) protein, two glycoproteins Gn and Gc, and an RNA-
dependent RNA-polymerase (RdRp), respectively [373].  Within the virion the three 
genome segments are individually encapsidated by N proteins to form ribonucloproteins 
(RNPs) [373-375].  Hantaviruses are spherical in shape with a grid-like pattern on their 
outer surface due to G1 and G2 heterodimers projecting from the lipid bilyaer surface of 
the virus.   
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ANDV and other hantaviruses primarily target vascular endothelial cells of the 
lung and macrophages for replication.  Entry is most often facilitated by attachment of 
the virus to β3 integrins on the surface of the cell, followed by endocytosis into the cell 
[376-378].  These may not be the only receptors for the virus because cells without β3 
integrin also allow hantavirus infection [379,380].  After internalization the virions are 
trafficked to either an early or late endosome.  The low pH of the endosome triggers a 
conformational change in the G2 glycoprotein allowing fusion of the viral and cellular 
membranes [381-383].  The viral genome, in the form of RNPs, is then released into the 
cytoplasm and transported to the site of viral replication within the cell [384,385].  This 
allows the viral genome to be used as a template in two different processes: transcription 
and replication.  Both transcription and replication are facilitated by the viral RdRp [386].  
Initially transcription is started by the viral RdRp to give rise to the S, M, and, L mRNAs.  
The S and L mRNA transcripts are then translated on free ribosomes, and the M segment 
transcript is translated on membrane-bound ribosomes, which is cotranslated on the rough 
endoplasmic reticulumn (RER) [351].  The glycoprotein precursor that results from 
translation of the M segment transcript is proetolytically processed into the G1 and G2 
glycoproteins during import into the ER [386,387].  The resulting G1 and G2 
glycoproteins are also glycosylated in the ER and then transported to the Golgi complex 
[387,388].  After the initial burst of transcription, the viral RdRp switches to replication 
of the viral S, M, and L genomic RNAs [351].  The first step in replication is transcribing 
the vRNA into complementary RNA (cRNA), which is then used as a template [383].  
Replication can then proceed using the cRNA de novo without the need for primers 
[386].  After the viral genome has been replicated it is then encaspidated by the N protein 
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to form RNPs [389].  When enough viral components have been made assembly can take 
place.  For New World hantaviruses it is most likely that assembly takes place at the 
Golgi complex where the G1 and G2 proteins accumulate, but evidence suggests that this 
step might also take place at the plasma membrane [390-392].  During assembly the 
RNPs for each genome segment along with L proteins come together and the virion buds 
inside of the Golgi, through the host membrane with G1 and G2 embedded in it, and is 
subsequently release into the mileu from the Golgi, probably by exocytosis [393].  
Alternatively the virion could bud directly through the plasma membrane, with G1 and G2 
embedded in it, entering the cellular mileu [392].  Infected cells are not lysed during 
infection with hantaviruses [394,395].   
HPS caused by ANDV 
Following infection of target cells, ANDV leads to HPS by indirect effects of the 
virus on endothelial cell barrier function.  Activation of the innate and adaptive immune 
responses leads to the production of proinflammatory cytokines and disease specific 
immunopathology.  The most damage caused by ANDV is focused on the lungs and 
typically presents as a quickly developing diffuse non-cardiogenic pulmonary edema 
[396].  The average incubation period for ANDV is 18-19 days with a possible range of 
11-32 days [397,398].  Current hantavirus diagnostic tests are capture ELISAs that detect 
the IgG/IgM response to the viral N protein [399,400].  For HPS infections the initial 
prodromal period lasts two to five days with symptoms of fever, headache, back pain, 
myalgia, and gastrointestinal symptoms [401].  Thrombocytopenia is one of the earliest 
laboratory findings of HPS, seen in more than 80% of patients, and can be detected as 
early as the prodromal phase of illness [402,403].  As the condition continues to worsen, 
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patients will begin to experience HPS specific respiratory symptoms such as cough, 
shortness of breath, tachycardia, and hypotension [402,404].  More severe 
cardiopulmonary symptoms arise from an increase in pulmonary edema and low cardiac 
output [405].  This can quickly lead to respiratory failure, often requiring treatment with 
supplemental oxygen, intubation, or intubation with mechanical ventilation [406].  The 
final stage of illness is the development of non-cardiogenic shock from the increased 
capillary permeability caused by inflammatory damage to the pulmonary vascular 
endothelium [404].  After the cardiopulmonary stage of illness, thrombocytopenia 
continues to be a detectable laboratory finding along with circulating immunoblasts, and 
elevated hematocrit values [407,408].  Gross pathological findings show that the lungs of 
patients with HPS are dense, rubbery, and heavy, usually weighing twice as much as the 
average lung [399].  Almost all deaths due to HPS occur 24-48 hours after the onset of 
cardiopulmonary symptoms and are a result of shock [351].  The mortality rate for HPS is 
approximately 50%, but it can vary depending on the specific hantavirus causing the 
infection [394,409].  If patients survive the acute phase of HPS, the convalescent period 
can be long; often patients experience weakness and fatigue with abnormal lung capacity.  
It may take months to years to fully return to normal [397,410].   
Despite the relatively high mortality rate there continues to be no virus- specific 
treatment or vaccine for HPS caused by ANDV.  This makes treatment for HPS only 
supportive in nature.  Patients often receive intravenous fluids and supplemental oxygen.  
Another setback to the development of a HPS treatment has been the lack of a quality 
rodent model of infection.  It was not until recently that a quality lethal rodent model of 
infection was developed.  ANDV causes a lethal disease in adult Syrian hamsters that 
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closely resembles disease in humans.  The Syrian hamster model has been a useful tool to 
study potential treatments and gain a better understanding of both the disease 
pathogenesis and the immune response to the virus [411].   
Immune Response to ANDV 
 The immune response is a necessary evil during a hantavirus infection: it is 
necessary to clear the infection, and develop immunological memory to prevent future 
infections, but it can also exacerbate the symptoms of infection.  Initially when a 
hantavirus infects a host cell it is recognized by various PRRs that will lead to the release 
of proinflammatory and anti-viral cytokines including type 1 IFNs and IFN-γ [412].  
These two groups of IFNs will work together as the first line of defense to restrict viral 
replication and spread of the virus.   
 Hantaviruses have developed several ways to evade the host IFN response 
including changing the look viral transcripts.  The viral G1 and G2 glycoproteins are able 
to down regulate the IFN pathways by inhibiting IRF-3 phosphorylation, dimerization, 
and nuclear transport, along with impairing the function of IKKe and TBK-1 kinases 
[413,414].   
 Infected macrophages are activated to produce cytokines such as TNF-α, IL-6, 
and IL-1 [351].  Those same cytokines along with IL-2 and IFN-γ can be detected in the 
lung tissues of patients with HPS during early stages of infection.  These cytokines are 
most likely being produced by infected macrophages and monocytes within the tissue 
[415].  In vitro, hantavirus infection of endothelium results in the induction of MCP-1, 
RANTES, and IP-10, all of which can recruit immune cell infiltrates to the lungs and 
other organs [395,416,417].  Furthermore, the excess of proinflammatory cytokine 
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production by immune cells is probably critical for HPS pathogenesis.  TNF-α is known 
to affect vascular permeability and results from clinical patients suggests that the IL-6 
plays a role in inhibiting cardiac function and inducing hypotension in HPS [351].   
 A robust CD4+ and CD8+ T-cell response is also activated against hantaviruses.  
CD8+ T-cells play a major role in the induction of HPS, whereas CD4+ T-cells play a 
more protective role by activating B-cells to produce protective neutralizing antibodies.  
Patients with severe HPS have higher amounts of virus- specific CD8+ T-cells present in 
their blood compared to patients with moderate disease, and those infected with other 
viruses [418].  T-cells obtained from patient’s blood primarily recognize epitopes within 
the N, G1, and G2 proteins [418-420], with the most immunodominant epitopes being part 
of the G1 protein [421].  Other studies indicate that G1- specific effector memory T-cells 
may contribute to protective immunity in ANDV infected patients [421].   
 Activation of the humoral immune response and production of neutralizing 
antibodies are essential to suppress hantavirus dissemination and to avoid fatal disease.  
Both IgM and IgG hantavirus- specific antibodies can be detected at or shortly after the 
onset of the prodromal period.  Initially, antibodies are derived against the N protein, and 
then later after the development of clinical symptoms almost all patients will develop 
IgM and IgG antibodies specific for the G1 protein [422].  It was shown that HPS patients 
with mild HPS had higher neutralizing antibodies titers to SNV or ANDV than those that 
with severe HPS [350,423].  Also, higher hantavirus specific IgG levels early in disease 
have been associated with survival [424].  After convalescence from hantaviral infection, 
humans are considered to be protected for life from reinfection [405].   
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 The importance of the humoral response in protection against HPS infections 
caused by the ANDV is further supported by the ability to passively transfer protection 
through the transfer of neutralizing antibodies.  Research has shown that plasma from 
HPS survivors is protective in the ANDV hamster model of infection [425].  Vaccine 
induced neutralizing antibodies collected from the serum of rhesus macaques or rabbits 
vaccinated with a DNA vaccine also protected against lethal disease development in the 
ANDV hamster model when given before or up to five days post-challenge [425,426].  
As a means to prevent the risks of reactionicity associated with the use of mammalian 
antibodies, duck IgY anti-ANDV antibodies were generated from the egg yolks of ducks 
vaccinated with a DNA.  The anti-ANDV IgY and IgY(ΔFc) antibodies were able to be 
used as a treatment in the ANDV Syrian hamster model of infection when administered 
after challenge [427].  These results provide direct evidence that goose- derived anti-
ANDV IgY antibodies can be used a passive antibody treatment against HPS caused by 
the ANDV.   
 Despite the encouraging studies that support the use of a passive treatment against 
HPS, current options are not fulfilling the need.  Human convalescent serum is in short 
supply, has risks of reactogenicity in humans, and is often contaminated with other 
infectious pathogens.  There are currently no neutralizing monoclonal antibodies 
available.  To fill this gap. this study demonstrates post-exposure treatment potential of 
goose-derived anti-ANDV antibodies both in vitro and in vivo.  In addition, the study 
identified epitopes within the ANDV glycoproteins recognized by IgY/IgY(ΔFc) 
antibodies purified from egg yolks of DNA vaccinated geese.  It is also shown that 
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neutralizing titers were maintained during the time period between initial and booster 
vaccination, and the neutralizing titers were increased after booster vaccination.   
 
Materials and Methods 
Virus and Cells 
 ANDV strain Chile-9717869 was propagated in Vero E6 cells (Vero c1008 
ATCC CRL 1586, Manassas, VA).  Cells were maintained in Eagle’s minimal essential 
medium with Earle’s salts (EMEM) (EMEM, supplemented with 10% FBS, 10mM 
HEPES (pH 7.4), 200U/mL penicillin, 200ug/mL streptomycin, 1x nonessential amino 
acids, 1.5μg/mL amphotericin B, and 50ug/mL gentamicin sulfate), at 37ºC humdified in 
a 5% CO2 incubator.  
Vaccination of Geese 
 Naïve geese were vaccinated with the ANDV DNA vaccine pWRG/AND-M(opt) 
(1mg) at two week intervals starting at day zero for ten weeks.  Injections were given 
intramuscularly (i.m.) using a needle free device (NFD).  One year later the same geese 
were booster vaccinated with either the same pWRG/AND-M(opt) or an optimized 
version of the same vaccine pWRG/AND-M(opt2).  Six 1mg injections were 
administered over a ten week time period.  Goose eggs were collected after initial 
vaccination and booster vaccination at time point indicated in figure 4. Sera was also 
collected from the vaccinated geese at five different time points both after the initial and 
booster vaccination series as indicated in figure 4.  
Epitope Determination 
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 Linear IgY epitopes were identified using JPT PepStar microarrays (JPT, Berlin, 
Germany).  The entire glycoprotein precursor sequence of the ANDV strain Chile-
9717869 was synthesized into 13 amino acid overlapping peptides.  The resulting 376, 
13-mer peptides were covalently attached to a microarray slide, with a 10 amino acid 
overlap between adjacent sample peptides.  Peptides were analyzed for their reactivity 
with IgY antibodies isolated from goose eggs, following protocols recommended by JPT.  
Briefly, slides were incubated with the primary antibody diluted to 30μg/mL at 4°C 
overnight in a moist environment.  The slide was washed and incubated with a 
fluorescently labeled secondary antibody, goat anti-chicken IgY conjugated to Cy5 
(1μg/mL) (Abcam, Cambridge, England) for 1 hour at 30°C.  After washing and drying 
the slide, bound antibodies were detected using a microarray reader (Genepix 4000).  
Fluorescence was measured at a 10μm pixel size and mean values with the background 
corrected were calculated and used for analysis.  The reactivity was classified based on a 
spectrum ranging from no activity in black, mild reactivity in gray, to strong reactivity in 
red. 
PsVNA 
 Pseudovirion assays (PsVNA) utilized a replication deficient vesicular somatic 
virus (VSV) coated with the ANDV glycoproteins and the VSV surface glycoprotein 
gene replaced with a Renilla luciferase reporter gene to be used for quantification.  The 
assay was completed as follows.  Vero cells were seeded at 1x104 cells/well in a 96-well 
plate and grown overnight.  Pseudovirions were pre-incubated with antibody treatments 
at 37ºC for 30 minutes before being added to cells.  The pseudovirion/antibody mixtures 
were incubated in wells containing cells for one hour at 37ºC, after one hour the 
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pseudovirion/antibody mixtures were removed and replaced with 200μL of fresh DMEM 
supplemented with 10% FBS.  Luciferace levels were measured 24 hours after infection 
using a luciferase assay system (Promega, Madison, WI).   
ANDV challenge of hamsters and passive treatment  
 Adult female Syrian hamsters (Mesocricetus auratus) were injected i.m. in the 
caudal thigh, using a 25-gauge 5/8-in. needle, with ANDV diluted in 0.2mL of sterile 
PBS (pH 7.4).  The challenge dose for ANDV was 2,000 PFU, which is 250 LD50 doses.  
Work involving ANDV infected hamsters was completed in a biosafety level 4 
laboratory.   
Five and eight days post-challenge hamsters were anesthetized by i.m injection with 
approximately 0.1mL/100g of body weight of a ketamine-acepromazine-xylazine 
mixture, and then subcutaneously (s.c.) injected with, one of the six following treatments: 
(1) anti-ANDV rabbit sera, (2) anti-ANDV goose sera, (3) anti-ANDV purified IgY, (4) 
normal goose sera, (5) normal purified IgY, or (6) no treatment.  The effects of challenge 
and subsequent antibody treatment on the survival outcome of the hamsters was assessed.   
 
Results 
Experimental Design 
 Previous work has demonstrated that anti-ANDV polyclonal IgY/IgY(ΔFc) 
antibodies from the eggs of vaccinated ducks limited the infection in the ANDV/Syrian 
hamster model when administered five to eight days after intranasal (i.n.) ANDV 
challenge [427].  This provides evidence for the use of anti-ANDV IgY antibodies as a 
post-exposure treatment for ANDV.  To further investigate the treatment potential of IgY 
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antibodies against ANDV infection and identify other sources for IgY, polyclonal IgY 
and IgY(ΔFc) antibodies were isolated from goose egg yolks.  Geese were vaccinated 
with an ANDV DNA vaccine, pWRG/AND-M (Fig 4A), that contains the full-length M 
genome segment of ANDV strain Chile- 9717869, at two-week intervals up until 8 weeks 
and then at 12 weeks using a needle-free device.  One year later the immune geese were 
booster vaccinated with either pWRG/AND-M or pWRG/AND-M(opt) at week 53, 54, 
56, 60, 61, and 62 (Fig 4B).  Eggs were collected from the vaccinated geese after the 
initial vaccination series and immediately after the long-range booster vaccination series. 
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Figure 4. Experimental design.  Geese were vaccinated i.m. with 1mg ANDV DNA 
vaccine pWRG/AND-M at 2 week intervals for 10 weeks, using a needle free device.  
One year later the same, geese were booster vaccinated again with 1mg ANDV DNA 
pWRG/AND-M(opt) or pWRG/AND-M(opt2) vaccine on weeks 52, 54, 56, 60, 61, and 
62.  Sera was collected from the vaccinated geese during the times indicated by red 
arrows.  Eggs were collected, after the initial vaccination series and after the booster 
vaccination as indicated by yellow ovals.  
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IgY Antibodies Isolated from Eggs of ANDV Vaccinated Geese Recognize Unique 
Epitopes On ANDV Glycoproteins G1 and G2 
 
 To determine the specificity of the IgY/IgY(ΔFc) antibodies purified from the egg 
yolks of vaccinated geese, epitope mapping was completed using microarray slides.  The 
M genome segment is the primary viral component of the ANDV DNA vaccine; two 
glycoproteins G1 and G2 are synthesized from the M segment and are present in dimers 
on the outside surface of mature ANDV virions.  Based on vaccine composition and virus 
structure it was hypothesized that antibodies produced by vaccinated geese would bind to 
epitopes present on the ANDV glycoproteins.  To identify potential epitopes on ANDV 
glycoproteins G1 and G2 recognized by anti-ANDV goose IgY and IgY(ΔFc) antibodies.  
Microarray slides were covalently linked with 13-mer peptides with a 10 amino acid 
overlap, for a total of 376 peptides, spanning the entire sequence of the glycoproteins 
from ANDV strain CHIL 9717869 (GenBank accession number AF291703).  Total 
IgY/IgY(ΔFc) antibodies from the egg yolks of geese receiving the initial vaccination 
series was separated into full length IgY antibody and the alternatively spliced IgY(ΔFc) 
antibody fractions for testing with microarray slides; unseparated IgY/IgY(ΔFc) 
combination was also tested.  IgY/IgY(ΔFc), IgY(ΔFc), or IgY/IgY(ΔFc) antibodies 
purified from the eggs of geese vaccinated at both initial and booster vaccination time 
points were incubated with microarray slides.  Reactivity was compared to negative 
control features on the slide that did not contain any protein; the average of the negative 
controls was taken and used for comparison.   
Eleven IgY/IgY(ΔFc) antibody reactive epitopes were identified across 
glycoproteins G1 and G2 (Fig. 3A and 3B).  Seven of the epitopes were specific for the G1 
glycoprotein, peptides starting with aa 121-130, 166-169, 205-211, 241-247, 511, 589, 
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and 613-625 (Fig 5), and the remaining four epitopes were within the G2 glycoprotein, 
reactive peptides started with aa 679-685, 727-745, 787-799, and 889-892 (Fig 6).  When 
comparing the epitopes recognized by IgY/IgY(ΔFc) antibodies to the separated IgY or 
IgY(ΔFc) antibodies, some of the epitopes were recognized exclusively by IgY(ΔFc) 
antibodies, (e.g., peptides aa 1024), while others were recognized by both even when 
separated and incubated with the microarray slides independently.  There were also some 
regions that elicited a higher reactivity from IgY antibodies versus IgY(ΔFc) antibodies 
(e.g., peptides starting with aa 121-130 and 166-169).  There was no reactivity detected 
with all negative control slide features (Fig 5 and Fig 6).   
Because geese receiving the booster vaccination showed increased neutralizing 
IgY antibody titers compared to the initial vaccination, we wanted to see if there was any 
change to the epitopes recognized by IgY/IgY(ΔFc) antibodies from the booster 
vaccinated geese.  Figures 5 and 6 (column 4) show that IgY/IgY(ΔFc) antibodies from 
the egg yolks of the booster vaccinated geese reacted with all of the same epitopes as the 
IgY/IgY(ΔFc) antibodies from the initial vaccination.  Reactivity of the booster 
IgY/IgY(ΔFc) antibodies with these epitopes was either at the same reactivity level or 
increased.  Additionally there were nine new regions of reactivity with the booster 
IgY/IgY(ΔFc) antibodies compared to all other IgY treatments, corresponding to peptides 
starting with aa 31-40, 82-85, 259, 355, 475, 484-493, 640, 691-697, and 940-955 (Fig 5 
and Fig 6).  One region of high reactivity was extended from seven peptides being 
recognized, start aa of 727-745, to 10 peptides 707-754.  This could be due to an 
additional epitope being recognized or an increase in the area of being recognized, after 
booster vaccination.  
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Sera from rabbits that were previously vaccinated with pWRG/AND-M were also 
incubated with microarray slides to determine potential epitopes recognized by 
mammalian antibodies generated after vaccination.  In general, the rabbit sera IgG 
antibodies recognized similar ANDV glycoprotein epitope regions as all IgY treatments.  
But, for a majority of the epitopes that were recognized by both rabbit sera IgG 
antibodies and goose egg IgY antibodies there was an obvious difference in reactivity.  
The rabbit IgG antibodies were less reactive than the IgY antibodies.  There was 
increased binding by the rabbit IgG antibodies to only one region, peptides starting with 
aa 313 and 358 in G1, when compared just to all IgY treatments (Fig 5).  Areas of notably 
decreased reactivity compared to all IgY treatments were found in both G1 and G2, 
specifically the peptides starting with aa 511, 589, and 685-697 (Fig 5 and Fig 6).  When 
comparing the reactivity of rabbit IgG antibodies to IgY/IgY(ΔFc) antibodies from the 
eggs of booster vaccinated geese, there was one obvious region of decreased reactivity in 
G1 corresponding to the peptide starting with aa 34 (Fig 5).  There were two unique 
epitope recognized strongly by the rabbit IgG antibodies compared to IgY/IgY(ΔFc) 
antibodies from the eggs of vaccinated geese comprised of peptides starting with aa 223-
229 in G1 along with peptide 760 in G2 (Fig 5 and Fig 6).   
Of the reactive epitopes identified, those with the highest reactivity were in the 
regions of peptides starting with aa 613-625 in G1 and peptides starting with aa 727-745 
in G2 (Fig 5 and Fig 6).  These two regions were recognized by all IgY treatments to the 
highest reactivity level.  These two regions were also recognized by the rabbit sera, but to 
a lesser reactivity level than all of the isolated IgY treatments.  Both of these highly 
reactive regions are outside of the regions identified as reactive by convalesecent human 
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sera from ANDV patients, and sera from naturally infected rodents [428].  Taken together 
these results show that IgY isolated from eggs yolks of vaccinated geese was ANDV 
specific and recognized unique epitopes compared to human and rodent serum.  
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Figure 5.  Identification of ANDV glycoprotein G1 epitopes.  Amino acid sequence for 
glycoproteins of ANDV strain Chile 9717869 used to make 13-mer peptides for 
microarray slide.  G1 microarray slides were incubated with IgY antibodies, IgY(ΔFc) 
antibodies, or IgY/IgY(Fc) antibodies isolated from egg yolks of vaccinated geese either 
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after the initial or booster vaccination series, or serum from vaccinated rabbits (first 
column- amino acid peptide starts with, second column- IgY antibodies from egg yolks 
after initial vaccination series, third column- IgY(ΔFc) antibodies from egg yolks after 
initial vaccination series, fourth column- IgY/IgY(ΔFc) antibodies from egg yolks after 
initial vaccination series, fifth column- IgY/IgY(ΔFc) antibodies from egg yolks after 
booster vaccination, sixth column- sera from DNA vaccinated rabbit).  Reactivity was 
measured based on a spectrum ranging from no activity in black, mild reactivity in gray, 
to strong reactivity in red (E-Empty features).
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Figure 6.  Identification of ANDV glycoprotein G2 epitopes.  Amino acid sequence for 
glycoproteins of ANDV strain Chile 9717869 used to make 13-mer peptides for 
microarray slide.  G2 microarray slides were incubated with IgY antibodies, IgY(ΔFc) 
antibodies, or IgY/IgY(Fc) antibodies isolated from egg yolks of vaccinated geese either 
after the initial or booster vaccination series, or serum from vaccinated rabbits (first 
column- amino acid peptide starts with, second column- IgYantibodies from egg yolks 
after initial vaccination series, third column- IgY(ΔFc) antibodies from egg yolks after 
initial vaccination series, fourth column- IgY/IgY(ΔFc) antibodies from egg yolks after 
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initial vaccination series, fifth column- IgY/IgY(ΔFc) antibodies from egg yolks after 
booster vaccination, sixth column- sera from DNA vaccinated rabbit). Reactivity was 
measured based on a spectrum ranging from no activity in black, mild reactivity in gray, 
to strong reactivity in red (E-Empty features).
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IgY/IgY(ΔFc) Antibodies From ANDV Vaccinated Geese are Capable of Virus 
Neutralization In Vitro 
 
Based on results from previous experiments showing the ability of IgY/IgY(ΔFc) 
antibodies from goose eggs to recognize epitopes on the ANDV glycoproteins, we next 
looked at the neutralizing capabilities of the antibodies.  Initially the ANDV-neutralizing 
abilities of anti-ANDV IgY/IgY(ΔFc) antibodies were determined for serum samples 
taken from vaccinated geese on weeks 0, 4, 6, 8, 10, and 12 using the in vitro PsVNA 
assay.  PsVNA80 results show that after the initial vaccination anti-ANDV IgY/IgY(ΔFc) 
antibodies were highly neutralizing with PsVNA80 titers ranging between 1,000 and 
10,000 just four weeks into the experiment (Fig. 7).  Neutralizing titer levels remained 
stable during all of the experimental time points, and titers were still detectable at week 
12 (Fig 7, right side week 0).  The neutralizing titers were also maintained during the year 
in between immunizations.  PsVNA80 titers of serum samples taken just prior to long-
range booster vaccination were similar to those of the vaccinated naïve birds.  
Surprisingly, when geese were given a booster vaccination, neutralizing antibody titers of 
the sera were increased to nearly 100,000 (Fig. 7).   
It has already been well established that in geese IgY is transferred from the sera 
to the egg yolk; because of this we predicted IgY/IgY(ΔFc) antibodies from the egg yolks 
of vaccinated geese would have similar ANDV neutralizing abilities as sera from 
vaccinated geese.  To test this PsVNA80 neutralizing titers were determined for 
IgY/IgY(ΔFc) antibodies isolated from eggs collected after the initial vaccination series 
and the long-range booster vaccination.  PsVNA80 titers for IgY/IgY(ΔFc) antibodies 
isolated from eggs collected after the initial series of vaccinations were within the same 
range as the sera from DNA vaccinated geese collected 1,000-10,000 (Fig 8).  After long-
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range booster vaccination series eggs were collected and IgY/IgY(ΔFc) from these egg 
yolks reached PsVNA80 titers of 100,000 for both geese boosted with pWRG/AND-
M(opt) and pWRG/AND-M(opt2) (Fig 8).  IgY/IgY(ΔFc) egg yolk PsVNA80 titers also 
correlate with the epitope mapping data that shows increased reactivity to nearly all of the 
epitopes recognized after the initial immunization, and additional regions of 
IgY/IgY(ΔFc) antibody binding after booster vaccination.  This data suggests that better 
neutralizing antibodies are made after the booster vaccination series.  
ANDV Specific Goose IgY/IgY(ΔFc) Antibodies Treat ANDV Challenged Syrian 
Hamsters In Vivo 
 
Based on the neutralizing capabilities of the goose anti-ANDV IgY/IgY(ΔFc) 
antibodies in vitro and previous success with passive treatment using duck IgY [427], we 
were interested in testing the goose anti-ANDV IgY/IgY(ΔFc) in vivo.  To test the in vivo 
therapeutic treatment potential of ANDV specific goose IgY/IgY(ΔFc) antibodies, groups 
of eight Syrian hamsters were lethally challenged i.m. with 250 LD50 doses of ANDV. 
Five and eight days later the hamsters were passively treated with one of the six 
following treatments: (1) anti-ANDV rabbit sera from DNA vaccinated rabbits (positive 
control), (2) anti-ANDV goose sera (from DNA vaccinated geese), (3) anti-ANDV 
purified IgY/IgY/(ΔFc) antibodies (from the eggs of DNA vaccinated geese), (4) normal 
goose sera, (5) normal purified IgY/IgY(ΔFc) antibodies, (6) no treatment (Fig 9A).  
Hamsters that receive normal goose sera, normal purified goose IgY, or no treatment 
started to die at day 12 with most of them dying by day 14.  In contrast, there was 100% 
survival in the groups of hamsters receiving either the anti-ANDV goose sera or anti-
ANDV purified IgY/IgY(ΔFc) antibodies.  The 100% survival in the ANDV- specific 
IgY treatment groups was just slightly better than the 90% survival for the anti-ANDV 
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rabbit sera, the difference was not statistically significant (Fig 9B).  These results 
demonstrate that anti- ANDV goose IgY/IgY(ΔFc) antibodies are capable of being used 
as a treatment for ANDV lethal challenge in vivo when administered five and eight days 
post-challenge in Syrian hamsters. 
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Figure 7. Neutralizing activity of anti-ANDV IgY/IgY(ΔFc) antibodies from serum of 
ANDV DNA vaccinated geese analyzed in vitro.  Neutralizing abilities of anti-ANDV 
IgY/IgY(ΔFc) antibodies in goose sera was measured by PsVNA.  On the left, PsVNA 
were run on sera collected during the initial vaccination series on weeks 0, 4, 6, 8, 10, and 
12.  On the right, PsVNA were run on sera collected before and after the booster 
vaccination series on weeks 52, 55, 56, 60, and 63.  ID and results for individual animals 
are shown where Group A has black lines and Group B has red lines.  Group A was 
boosted with pWRG/AND-M(opt) and Group B was boosted with pWRG/AND-M(opt2). 
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Figure 8. In vitro neutralizing activity of anti-ANDV IgY/IgY(ΔFc) antibodies isolated 
from the eggs of ANDV DNA vaccinated geese.  Neutralizing activity of IgY/IgY(Fc) 
isolated from the individual eggs of geese after initial and booster DNA vaccination was 
measured by PsVNA.  PsVNA values for IgY/IgY(ΔFc) isolated from eggs collected 
from geese after initial vaccination are to the left of the center and to the right are PsVNA 
values for IgY/IgY(ΔFc) from eggs collected after booster vaccination.  Each sample was 
run in triplicate and bars represent standard deviation. 
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Figure 9.  Anti-ANDV IgY/IgY(ΔFc) antibodies purified from goose eggs treats hamsters 
against lethal ANDV challenge when administered after challenge.  A) Experimental 
design.  Six groups of eight hamsters were challenge with 250 LD50 of ANDV by i.m. 
route on day 0.  Groups of eight hamsters were then passively treated with the indicated 
material on days five and eight post-challenge.  Sera from a previously ANDV vaccinated 
rabbit served as a positive control.  B) Survival curve of hamsters that were challenged 
and then passively treated.
A 
Group 1: anti-ANDV rabbit sera (+ control) 
Group 2: anti-ANDV goose sera 
Group 3: anti-ANDV purified IgY 
Group 4: normal goose sera 
Group 5: normal purified IgY 
Group 6: no treatment  
B 
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Discussion 
ANDV has been associated with most HPS cases [363] and continues to be the 
only hantavirus capable of human-to-human transmission.  In spite of the continuing 
number of HPS cases and the staggering mortality rate of approximately 40%, there are 
no available treatments or preventative vaccines.  The potential for the use of passive 
treatments to protect against HPS has already been established by previous studies 
utilizing immune serum from infected patients and isolated antibodies from vaccinated 
animals in the ANDV/hamster model [425-427].  In addition, research using HPS patients 
has highlighted the importance of neutralizing antibody production in recovery from 
infection [423,424].  A clear source of antibodies for passive treatment would be immune 
plasma from recovered patients, but immune plasma is in short supply, can pose 
problems of reactogenicity when given to other patients, and can be contaminated with 
other infectious pathogns.  Protective monoclonal antibodies are another option for 
treatment and have been used with other viral infections [429], but thus far there have 
been no identified ANDV-neutralizing monoclonal antibodies.   
As an alternative source, polyclonal antibodies have been generated against toxins 
and venoms in vaccinated sheep and horses, but this method has yet to be successful in 
generating any anti-viral treatments.  Avian antibodies are again a logical alternative 
source of passive therapeutics with the potential to overcome the shortcomings of current 
therapeutic antibodies be it limitations in source, reactivity to Fc portions of mammalian 
antibodies, or lack of reactivity with neutralizing epitopes.  IgY is the primary serum 
antibody of birds and is transferred to the egg yolk via receptors on the surface of the 
yolk membrane, that is specific for IgY antibody translocation, causing the yolk to have 
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high IgY antibody concentrations [21,25-27,44].  IgY can then be purified from egg yolks 
and in large quantities for use as therapeutics.  Current and previous research using 
polyclonal avian IgY antibodies has already established a baseline for its therapeutic 
potential against infectious agents e.g. Pseudomonas aeruginosa [66,108,120,430] and 
Candida albicans [431].  IgY antibodies have also been developed against different 
venoms and antitoxins [202,205,206,432-434].  Most important for our research, DNA 
vaccinated birds have also been used to produce virus- specific IgY antibodies 
[427,435,436].   
There was a direct relationship between the ANDV neutralizing titers of 
IgY/IgY(ΔFc) antibodies from both the serum and eggs of vaccinated geese after the 
initial and booster vaccination series.  PsVNA80 titers for sera from DNA vaccinated 
geese increased from a range of 1,000-10,000 just four weeks into the initial vaccination 
series, to nearly 100,000 three weeks into booster vaccination (Fig 7).  In this current 
study, it has also been shown that neutralizing titers were maintained during the year in 
between initial vaccination and booster vaccination.  Neutralizing titers measured 12 
weeks into the initial vaccination series and just prior to booster vaccination stayed in the 
1,000-10,000 range for PsVNA80 values (Fig 7).  These results are important because 
during a typical response most animals and humans show a decrease in antibody titers a 
few weeks after vaccination and a drop would certainly be expected a year after 
vaccination.  More importantly, when geese were booster vaccinated, IgY/IgY(ΔFc) 
antibodies from the sera of some geese reached PsVNA80 neutralizing titers of 100,000 
(Fig 7).  Similar trends were observed for PsVNA80 titers of goose anti-ANDV 
IgY/IgY(ΔFc) antibodies isolated from the eggs of vaccinated geese.  After initial 
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vaccination PsVNA80, titers for individual eggs ranged between 1,000 and 10,000.  
Booster vaccination resulted in an increase in egg IgY/IgY (ΔFc) antibody titers to nearly 
100,000 (Fig 8).  In similarly designed experiments Brocato et al. reported that DNA 
vaccination of ducks with pWRG/AND-M resulted in the production of ANDV 
neutralizing antibodies[427].  But, ANDV specific duck IgY/IgY(ΔFc) antibodies 
purified from egg yolks of vaccinated ducks only reached neutralizing PRNT80 titers of 
10,240.  These neutralizing titer values were lower than the neutralizing ANDV goose 
IgY antibody titers obtained in this study.  Current results point out the advantage of 
administering a long-range booster vaccination in the use of pWRG/AND-M and that 
IgY/IgY(ΔFc) antibodies purified from egg yolks after booster vaccination represent a 
better option for post-exposure IgY antibody treatments due to the increased neutralizing 
capabilities of the antibodies.  
Epitope mapping completed using IgY/IgY(ΔFc), IgY, and IgY(ΔFc) antibodies 
purified from egg yolks of vaccinated geese identified several regions of reactivity on the 
ANDV surface glycoproteins G1 and G2.  Some of these regions are likely to represent 
neutralizing ANDV epitopes.  In other hantavirus infections, neutralizing activity has 
been related to antibodies directed to the surface proteins.  Monoclonal antibodies to G1 
and G2, but not to N, have been shown to neutralize viral infection in vitro [437].  This 
matches what is seen in natural hantavirus infections in humans, where antibodies are 
made predominantly against the N protein, followed by the glycoproteins [438,439].   
From the initial vaccination there were 11 epitopes recognized by IgY/IgY(ΔFc) 
antibodies and after the long-range booster vaccination there were an additional nine 
epitopes recognized by IgY/IgY(ΔFc) antibodies.  There were two regions with the 
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highest reactivity; for all IgY antibody treatments, spanning peptides starting with aa 
613-625 in G1 and aa 727-742 in G2.  Looking at the predicted structure of the ANDV 
glycoproteins as part of a mature virion, aa 613-625 are part of the endomembrane 
domain prior to the WAASA cleavage site.  This cleavage site is found at aa 647-651, 
where the glycoprotein precursor is cleaved into the two glycoproteins G1 and G2 [428].  
The secondary structure of this region is predicted to be primarily α-helices.  For the G2 
glycoprotein’s highly reactive region, aa 727-742, is within the outer membrane domain 
of the protein and the secondary structure primarily made of β-sheets and random coils.  
The highly reactive regions in glycoproteins G1 and G2 do not overlap with regions 
previously identified as reactive by serum from human ANDV HPS patients, or serum 
from naturally infected rodents [428].  In addition, the highly reactive IgY antibody 
epitopes do not overlap with regions recognized by monoclonal antibodies (mAb) which 
neutralize other hantaviruses [440-442].  The only overlap with human and rodent 
epitopes was seen with IgY/IgY(ΔFc) anitbodies from egg yolks after long-range booster 
vaccination, specifically aa 691-710.  After initial vaccination, this region was hardly 
recognized by IgY/IgY(ΔFc) antibodies, but after long–range booster vaccination 
IgY/IgY(ΔFc) antibody reactivity increased, especially the peptide starting with aa 694, 
which reached the highest reactivity potential (Fig 6).  This is a potentially 
immunodominant domain since it is being recognized by antibodies from multiple 
species.  The other two highly reactive regions recognized by the IgY/IgY(ΔFc) 
anitbodies from the egg yolks of booster vaccinated geese, represent novel, potentially 
neutralizing epitopes on the ANDV glycoproteins that can be used in the future to 
develop mAb therapies.  
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Future work will focus on using results from the epitope mapping experiments to 
develop cocktails of ANDV neutralizing mAbs.  A treatment that has the potential to be 
more effective could be developed by specifically targeting epitopes that are neutralizing.  
This can lower the total antibody dose that needs to be administered and in turn lowers 
the chance of any adverse reactions to the treatment.  This, coupled with the decreased 
reactogenicity due to the natural properties of goose IgY antibodies, leads to the 
opportunity to develop an all-around better treatment option for ANDV and other viral 
agents. This potential has been previously explored in our lab with Dengue virus and 
West Nile Virus (data not shown).   
 Previous research has already established the success of passive treatments for 
ANDV infection utilizing sera from animals vaccinated against ANDV.  When passively 
transferred to Syrian hamsters one day prior to lethal challenged with ANDV (250 LD50 
i.m.), serum from rehesus macaques vaccinated against ANDV was able to protect 
against infection [425].  The same serum was also able to reverse ANDV infections when 
administered either four or five days after challenge [425].  During this study the post-
exposure treatment potential of plasma from a Chilean ANDV HPS patient that was 
collected during the convalescent-phase was also compared.  When the convalescent 
plasma was administered at four or five days post-challenge only 50% of hamsters 
survived.  Through previous survival studies in ANDV challenged hamsters using 
IgY/IgY(ΔFc) antibodies from the eggs of ducks vaccinated with pWRG/AND-M, it was 
concluded that high doses of ANDV- specific IgY/IgY(ΔFc) antibodies administered 
within eight days of exposure to virus is sufficient to contain and suppress the infection 
[427].  Notably, in this research, anti-ANDV goose IgY/IgY(ΔFc) antibodies were 
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administered at five and eight days post-challenge with ANDV in hamsters and there was 
100% survival, while treatment with non-specific IgY antibodies, or no treatment led to 
death of nearly all the hamsters in those treatment groups (Fig 9).   
These results demonstrate the in vivo efficacy of ANDV specific goose 
IgY/IgY(ΔFc) antibodies and the successful coupling of DNA vaccination with the 
extraction of therapeutic antibodies from the eggs of vaccinated geese.  ANDV specific 
goose IgY/IgY(ΔFc) antibody treatments had a slightly better survival percentage than 
the anti-ANDV rabbit sera treated group.  Therefore it is possible that antibodies from 
vaccinated animals have better virus neutralizing capabilities than those found in human 
convalescent serum, or that the antibody response is being directed towards highly 
neutralizing epitopes as a result of vaccination.  To further support this, Brocato et al. 
also showed that IgY/IgY(ΔFc) antibodies isolated from the eggs of vaccinated ducks had 
higher plaque reduction values at lower concentrations than fresh frozen plasma (FFP) 
from a survivor of ANDV HPS[427].   
This research demonstrates the potential to use goose IgY/IgY(ΔFc) antibodies as 
a post-exposure treatment for HPS caused by ANDV.  Results both in vitro and in vivo 
clearly show the viral specificity and neutralizing capabilities of the anti-ADNV goose 
IgY antibodies.  The decreased reactivity of IgY antibodies in the mammalian system 
makes it an ideal alternative to the rare and potentially dangerous human FFP.   
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CHAPTER IV 
SAFETY OF GOOSE IGY FOR USE IN THE MAMMLIAN SYSTEM 
Introduction 
 It has been demonstrated that avian IgY/IgY(ΔFc) antibodies do not interact with 
the human complement system, rheumatoid factor (RF), or bacterial pathogens that are 
Fc-binding, and generate less of a human anti-murine antibodies (HAMA)/anti-drug 
antibody (ADA) response than mammalian IgG antibodies.  This lack of reactivity in the 
mammalian system is mostly due to the structure of the Fc portion of avian IgY/IgY(ΔFc) 
antibodies and how it differs from mammalian IgG.   
HAMAs form often when antibodies are used for treatment or imaging; the 
murine antibody is seen as a foreign protein by the human body, which triggers an 
immune response resulting in the formation of HAMAs.  In some cases HAMAs have 
also been found in the serum of patients who have not been treated with antibodies [66].  
The HAMA response can persist in the blood for several months, and can be easily 
reactivated if memory B-cells are formed.  This response can interfere with assays used 
in diagnosis and/or surveillance of disease as well as cause potentially painful symptoms 
for the patients.  Even engineered antibodies have protein epitopes that can be seen as 
immunogenic by the immune system and ultimately cause an antibody response by the 
body.  The HAMA/ADA responses within the body can result in a variety of symptoms 
from more mild allergic reactions, generalized pain, hyponatremia, fever, rigors, chills, 
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rash, paresthesia, weakness, chronic refractory postural hypotension [67,68], to 
hypersensitivity reactions that range from serum sickness with urticarial and 
bronchosapsms [68-72] to anaphylactic shock [73-75].   
The structural differences between mammalian IgG antibodies and avian IgY 
antibodies are especially important in their interactions with complement proteins and 
RF.  The heavy chain of the full length IgY antibody is made up of one variable domain 
and four constant domains, three of which make up the Fc region.  The alternatively 
spliced (IgY(ΔFc)) antibody isotype has one variable domain and one constant domain 
[44].  In contrast, the heavy chain of mammalian IgG antibody has one variable domain 
and only three constant domains, two of which make up the Fc region [44].  The 
interaction of mammalian IgG antibody with complement proteins and RF can result in 
unwated inflammatory reponses in the body. When the complement pathway is 
inappropriately activated it can lead unnecessary inflammatory reactions.  The 
anaphylatoxins, C4a, and C5a, products of the complement pathway, are often 
responsible for initiating parts of these inflammatory responses.  Anaphylatoxins are able 
to stimulate mast cells to trigger IgE-independent histamine release as well as TNF-α 
release [89], wich can mimic allergic shock depending on the number of mast cells 
involved [90,91].  In humans, a Serum sickness-like illness can also develop depending 
on the number of complement immune complexes formed during the course of treatment.   
Most studies on the differences in the reactivity of avian, compared to 
mammalian, immunoglobulin have been performed in vitro. In ELISAs comparing goat 
and chicken antibodies as capture antibodies to normal human serum (NHS), it has been 
shown that complement activation blocked up to 50% of antigen binding when using goat 
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antibodies, but an active complement system had no effect on antigen binding when 
chicken antibodies were used as a capture antibody [94].  In sandwich ELISAs used for 
the detection of antigens in human samples, the anti-mammalian IgG antibody RF can 
interfere and cause false positive results.  These false positives can be avoided by the use 
of avian IgY antibodies [84].   
The aim of this research is to determine the reactivity of goose IgY/IgY(ΔFc) and 
IgY(ΔFc) antibodies within the mammalian system utilizing in vitro peripheral blood 
monocyte assays, neutrophil assays, and in vivo injection studies to look at organ 
pathology for any damage due to inflammation.  Previous research has proven the 
effectiveness of goose IgY/IgY(ΔFc) antibodies as potential treatments.  The next step to 
using goose IgY/IgY(ΔFc) antibodies as human passive antibody treatments is to 
establish their safety.  We show here for the first time in vitro and in vivo experiments 
testing the reactivity of IgY within the mammalian system.   
 
Materials and Methods 
Mice  
 Mice were injected intravenously (i.v.) with either 200μg of goose IgY in 200μL 
of 1X PBS pH 7.4 (Invitrogen, Carlsbad, CA, USA) or 200uL of 1X PBS alone on 
experimental day 0.  Tissues were collected from IgY injected mice on experimental days 
0, 6hr, 2, 4, 7, 14, and 28.  Tissues were collected from control injected mice, PBS alone, 
on experimental days 0 and 14.  On day 28 mice were euthanized and the following 
tissues were collected: brain, heart, lung, liver, spleen, and kidney.  Blood was collected 
from mice prior to euthanization.   
Histology 
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Mouse tissues were fixed in a 10% neutral buffered formalin solution (Fisher 
Scientific, Hampton, NH, USA).  Fixed tissues were sent to AML laboratories 
(Baltimore, MD, USA) for paraffin embedding, sectioning, and hematoxylin and eosin 
staining.  Stained tissues sections were then viewed and scored by a blinded pathologist.   
Rabbits 
 Thirty adult female rabbits were divided into three experimental groups and one 
control group.  Rabbits in experimental group one were injected with 10mg of 
commercially available human anti-rabies antibody HRIG, HyperRAB® (Grifols, Los 
Angeles, CA, USA ).  Rabbits in experimental group two were injected with 10mg of 
total goose anti-rabies IgY antibodies (IgY/IgY(ΔFc)).  Rabbits in experimental group 
three were injected with goose anti-rabies IgY(ΔFc).  Rabbits in the control group were 
inject with 1X PBS, p.H. 7.2.  Treatments were administered via i.m. injections on 
experimental days 0, 7, 14, 28, and 42.  Sera was collected from treated rabbits on 
experimental days 0, 14, 28, and 42.  Four weeks after the last injection, experimental day 
70, rabbits were terminally bled and euthanized.  The spleen, thymus, lymph nodes, 
kidneys, hearts, liver, and brain were collected, fixed, H&E stained, and scored by a 
blinded pathologist.  
Human PBMC Cell Culture  
 Peripheral blood monocytes (PBMCs) were isolated from whole blood of healthy 
human donors and resuspended at a concentration of 2.0x106 cells/mL in RPMI 1640 
culture media supplemented with 2mM L-glutamine, 10mM HEPES, 100ug/mL 
streptomycin, and 100U/mL penicillin.  Then, 500μL of the cell suspension was added to 
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wells of a 24-well tissue culture plate.  Next, 500μL of cell treatment at twice the final 
concentration in culture media or an additional 500μL of cells (negative control) was 
added to the wells.  Cells were treated with lipopolysaccharide (LPS) (10μg/mL), 
mammalian IgG antibody (10μg/mL), and goose IgY/IgY(ΔFc) antibody (10μg/mL).  
Plates were incubated for 72 hours at 37ºC with 5% CO2.  Culture supernatants were 
collected at 12, 24, 48, and 72 hours and frozen for later cytokine analysis.   
Human Neutrophil Cell Culture 
 Neutrophils were isolated from healthy human blood using Histopaque (Sigma 
Aldrich, MO, USA).  Isolated neutrophils were resuspened in RPMI 1640 containing 1% 
BSA at a concentration of 5x105 cells per mL.  Then, 100uL of cell suspension was added 
to wells of a 96-well tissue culture plate.  Cells were treated with PMA diluted 1:1000 
(positive control), culture media alone (negative control), LPS (10μg/mL), mammalian 
IgG antibody (10μg/mL), and goose IgY/IgY(ΔFc) antibody (10μg/mL).  Plates were 
incubated for 72 hours at 37ºC with 5% CO2.  Culture supernatants were collected at 12, 
24, 48, and 72 hours and frozen for later analysis.  Elastase levels in culture supernatants 
were quantified using a fluorometric assay kit (Cayman Chemical, Ann Arbor, MI, USA).  
Cytokine Analysis 
 Cytokine levels in culture supernatants were quantified by ELISA using 
commercially available kits.  The IL-1β kit was obtained from R&D systems, 
Minneapolis, MN.  TNF-α and IL- 10 levels were quantified using BD Opt-EIA™ 
ELISA kits (BD Biosciences, San Diego, CA, USA).  Nitric oxide (NO) levels in the 
culture supernatant were measured through a Griess assay utilizing a commercially 
available kit from Promega, Madison, WI.  The colorimetric change of each well was 
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determined at various optical densities using a Thermomax Microplate Reader 
(Molecular Devices, Sunnyvale, CA, USA).  
Statistical Analysis 
 Statistical analysis was carried out using the two-way ANOVA and Bonferroni’s 
multiple comparison tests.  P value <0.05 was considered statistically significant unless 
otherwise noted.  Data was plotted as calculated sample means with standard deviation.   
 
Results 
Injection of IgY/IgY(ΔFc) Antibodies Does Not Induce Abnormal Organ Pathology 
in Vivo 
 
The effects of single and multiple injections of avian IgY/IgY(ΔFc) antibodies on 
organ pathology was examined in vivo.  In the single injection study, mice were injected 
with either goose IgY/IgY(ΔFc) antibodies (n=35) or 1X PBS (n=10) via tail vein 
injection on experimental day 0.  Organs collected from the experimental mice, included 
the brain, heart, lung, liver, spleen, and kidney; tissue was fixed, stained with H&E, and 
reviewed by a blinded pathologist.  Of the six organs that were collected, there were no 
abnormal changes found in the brain, heart, liver, kidney, or spleen.  The only tissue that 
showed any abnormalities was the lungs.  Pulmonary hemorrhages were present in a large 
number of mice, across both treatment groups.  The frequency and severity of 
hemorrhages in the lungs was increased on days 14 and 28 (Table 1).   
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Table 1. Pathology results from single injection study in mice.  
Results are shown for two pathology slides from a sample size of five mice for each 
experimental time point.  
1 no change  
2 focal hemorrhage (FH) in two of five mice  
3 acute inflammation of renal pelvis (ARP) in one of five mice 
4 small cyst (SC) 
5 moderate hemorrhage (MH) in one of five mice  
 
Rabbits were injected in a multiple injection study, receiving five injections over 
a six-week period with either goose anti-rabies IgY/IgY(ΔFc), goose anti-rabies 
IgY(ΔFc), human anti-rabies antibodies (HRIG), or control 1X PBS.  Four weeks after 
the last injection (day 70), all rabbits were euthanized and organs were collected 
including the spleen, thymus, lymph nodes, kidneys, heart, lungs, liver, and brain.  Rabbit 
tissues were scored by a blinded pathologist for inflammation.  Inflammation was almost 
PBS  Brain Heart Liver Spleen Kidney Lung 
 0 hours -/-1 -/- -/- -/- -/- 2FH/2FH2 
 14 days -/- -/- -/- -/- ARP/ARP3 2FH/2FH 
        
IgY/IgY(ΔFc)  Brain Heart Liver Spleen Kidney Lung 
 0 hours -/- -/- -/- -/- -/- -/- 
 6 hours -/- -/- -/SC4 -/- -/- FH/FH 
 2 days -/- -/- -/- -/- -/- 3FH/3FH 
 4 days -/- -/- -/- -/- -/- 2FH/2FH 
 7 days -/- -/- -/- -/- -/- 3FH/3FH 
 14 days -/- -/- -/- -/- -/- 3FH/3FH, 
1MH/1MH5 
 28 days -/- -/- -/- -/- -/- 4FH/4FH, 
1MH/1MH 
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exclusively limited to the lungs of experimental rabbits, but there was no difference 
observed between treatment groups.  Overall, the pathology results indicated that rabbits 
receiving multiple injections with either IgY/IgY(ΔFc) or IgY(ΔFc) antibodies showed 
no signs of abnormal pathology when compared to the rabbits that received multiple 
injections of HRIG or 1X PBS (Table 2).  The results of the single and multiple injection 
studies further support the non-inflammatory nature of avian IgY in the mammalian 
system.  
Table 2. Pathology results for organs collected from rabbits in the multiple injection 
study.  
Rabbit Brain1  Thymus2 Lung3 Heart4 Liver5 Kidney6 Spleen7 Treatment 
1 0 0 2 0 0 0 0 HRIG 
2 0 0 3 0 0 0 0 HRIG 
3 0 0 1 0 2 0 0 HRIG 
4 0 0 0 0 0 0 2 HRIG 
5 0 0 0 0 0 0 0 HRIG 
6 0 0 2 0 0 0 0 HRIG 
7 0 0 0 0 0 0 0 HRIG 
8 0 0 2 0 0 0 2 HRIG 
9 0 0 0 0 0 0 0 IgY/IgY(ΔFc) 
10 0 0 2 0 0 0 0 IgY/IgY(ΔFc) 
11 0 0 2 0 0 0 1 IgY/IgY(ΔFc) 
12 0 0 1 0 0 0 1 IgY/IgY(ΔFc) 
13 0 0 0 0 0 0 1 IgY/IgY(ΔFc) 
14 0 0 1 0 0 2 0 IgY/IgY(ΔFc) 
15 0 0 1 0 0 0 2 IgY/IgY(ΔFc) 
16 0 0 2 0 1 0 1 IgY/IgY(ΔFc) 
17 0 0 0 0 0 0 0 IgY(ΔFc) 
18 0 0 0 0 0 0 0 IgY(ΔFc) 
19 0 0 2 0 0 0 0 IgY(ΔFc) 
20 0 0 1 0 0 0 0 IgY(ΔFc)c 
21 0 0 0 0 0 0 0 IgY(ΔFc) 
22 0 0 3 0 0 0 0 IgY(ΔFc) 
23 0 0 1 0 0 0 2 IgY(ΔFc) 
24 0 0 1 0 2 0 1 IgY(ΔFc) 
25 0 0 2 0 0 0 0 PBS 
26 0 0 2 0 0 0 0 PBS 
27 0 0 2 0 0 0 0 PBS 
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28 0 0 0 0 0 0 0 PBS 
29 0 0 1 0 0 0 1 PBS 
30 0 0 2 0 0 0 0 PBS 
1,4,6 Brain, Kidney, and Heart: 0= no change; 1= minimal change; 2= mild change; 3= 
moderate change; 4= marked changes but restricted extent; 5= marked and widespread 
changes; 6= very severe, diffuse changes  
3 Lung: 0= no change; 1= minimal change (or possible non-specific background or 
appearance compounded by lung collapse i.e. not inflated); 2= mild inflammation and/or 
pneumocyte hypertrophy; 3= moderate inflammation inflation and/or pneumocyte 
hypertrophy; 4= marked inflammation and/or pneumocyte hypertrophy; 5= severe 
inflammation and/or pneumocyte hypertrophy < 50% of lung lobe  
7 Spleen: 0= no change; 1= mildly increased extramedullary hematopoiesis (EMH); 2= 
moderately increased EMH and/or mild inflammation; 3= marked EMF and/or moderate 
inflammation; 4= marked inflammation; 5= severe inflammation; 6= severe necrotizing 
inflammation.  
 
IgY/IgY(ΔFc) Antibodies Do Not Induce Notable Proinflammatory Mediator 
Release From Human PBMCs or Neutrophils 
 
To better understand the reactivity of avian IgY/IgY(ΔFc) in the mammalian 
system and the capacity of avian IgY/IgY(ΔFc) antibodies to activate human immune 
cells and initiate an inflammatory reaction, human PBMCs and neutrophils were isolated 
from healthy human blood and then incubated in vitro with mammalian IgG antibodies or 
avian IgY/IgY(ΔFc) antibodies, and cells incubated with LPS served as a positive control 
and cells alone as a negative control.  Culture supernatants were collected 0, 12, 24, 48, 
or 72 hours from start of incubation depending on the analysis being completed.  Culture 
supernatants collected from treated PBMCs were analyzed for the release of cytokines, 
including proinflammatory cytokines IL-1β and TNF-α, anti-inflammatory cytokine IL-
10, and nitric oxide (NO).   
IL-1β was not detected as a result of IgY/IgY(ΔFc) antibody treatment at 12, 24, 
and 48 hours post-treatment, with a modest level of IL-1β observed at 72 hours (Fig 10).  
This is compared to a consistent amount of IL-1β being produced by mammalin IgG 
 
Table 2. Cont. 
Table 2. Cont. 
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treated PBMCs as indicated by the 5pg/mL concentration present in culture supernatants 
from 12 hours post-treatment to the final time point, and gnificant amounts of IL-1β 
generated by LPS treatment of PBMCs.  TNF-α was not detected via ELISA in the 
culture supernatants collected from PBMCs incubated with IgY/IgY(ΔFc) antibodies (Fig 
11).  In contrast, TNF-α levels from cells incubated with LPS were at high throughout 
with the highest levels being measured at 72 hours post-treatment.  The difference 
between the LPS treated PBMCs and all other groups was statistically significant.  Only 
at one point, 24 hours post-treatment, did IgG treated PBMCs produce any TNF-α (Fig 
11).  The difference between IgY/IgY(ΔFc) antibody and IgG antibody treated cells was 
not significant.  The IL-1β and TNF-α results correlate with the pathology results from 
the single and multiple injection studies,  supporting the finding that IgY/IgY(ΔFc) 
antibody does not cause abnormal inflammatory responses.  Levels of the anti-
inflammatory cytokine IL-10 were also quantified in culture supernatants from treated 
PBMCs.  No IL-10 was detected by ELISA with all treatments at all time points (data not 
shown).   
 Nitrite levels in culture supernatants collected from PBMCs were quantified as an 
indicator of NO production by the cells.  Cells treated with IgY/IgY(ΔFc) antibodies 
showed a peak in nitrite levels at 24 hours with levels decreasing afterward (Fig 12).  IgG 
antibody treated cells showed a stable increase in nitrite levels from 0 hours all the way 
up to 72 hours of incubation.  There was no noticeable difference in the nitrite levels in 
culture supernatants collected from cells incubated with IgY/IgY(ΔFc) antibodies 
compared to those incubated with IgG antibodies.  The nitrite levels generated by 
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IgY/IgY(ΔFc) antibody treatment of PBMCs were well below a level of concern during 
an inflammatory response.   
The potential reactivity of IgY/IgY(ΔFc) with human neutrophils was also 
assessed.  Neutrophils were isolated from the blood of healthy human donors and then 
co-cultured in vitro with mammalian IgG antibodies, avian IgY/IgY(ΔFc) antibodies, 
PMA (which is known to activate neutrophils leading to elastase release), and LPS.  
Untreated cells, served as a negative control.  Activation of neutrophils by the various 
treatments was determined by the amount of elastase present in neutrophil culture 
supernatants at 12, 24, and 72 hours after treatment.  Treatment of cells with 
IgY/IgY(ΔFc) antibodies resulted in the release of elastase by neutrophils, but levels were 
lower than all other treatments at 12 hours and slightly lower than all other groups at 72 
hours as well (Fig 13).  There was no difference in the release of elastase between 
neutrophils treated with mammalian IgG and those treated with IgY/IgY(ΔFc). 
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Figure 10.  IL-1β concentration in culture supernatants from treated human PBMCs.  IL-
1β levels were analyzed in culture supernatants collected from PBMCs stimulated with 
mammalian IgG antibodies, goose IgY/IgY(ΔFc) antibodies, LPS (positive control), or 
cells only (negative control).  IL-1β levels were quantified using an ELISA.  Culture 
supernatants were collected at hours 0, 12, 24, 48, and 72 hours post-treatment of cells.  
Each data set is a mean of three samples with the bars representing the standard 
deviation.  Two-way ANOVA and Bonferroni’s Multiple Comparison tests were 
completed for statistical analysis.  ( ⃰ ) indicatates significant distances between 
IgY/IgY(ΔFc) treatment of cells and LPS treatment of cells (P< 0.001).   
 
⃰ 
⃰ 
⃰ 
⃰ 
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Figure 11.  TNF-α levels in culture supernatants from treated human PBMCs.  PBMCs 
were treated with either goose IgY/IgY(ΔFc) antibodies, mammalian IgG antibodies, 
LPS, or left untreated.  Culture supernatants were collected 0, 12, 24, 48, and 72 hours 
after incubation.  TNF-α levels in the culture supernatants were quantified using an 
ELISA.  ( ⃰ ) indicates a significant difference between IgY/IgY(ΔFc) treated PBMCs and 
LPS treated PBMCs (P< .0001).  Statiscal analysis completed was a Two-way ANOVA 
and Bonferroni’s Multiple Comparison tests.  
⃰ ⃰ 
⃰ 
⃰ 
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Figure 12. Nitrite concentration in culture supernatants from treated human PBMCs.  A 
Griess assay measuring nitrite concentrations in culture supernatants was used as an 
indicator of the amount of nitric oxide released by treated PBMCs. Culture supernatants 
were collected from PBMCs treated with goose IgY/IgY(ΔFc) antibodies, mammalian 
IgG antibodies, LPS, or untreated cells.  Nitrite levels in the culture supernatants 
collected at 0, 12, 24, 48, and 72 hours post-treatment were quantified using a Griess 
assay; absorbance was read at an OD between 520 to 540nm.  The mean for each data 
point is shown, with the bars representing the standard deviation. 
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Figure 13.  Neutrophil elastase levels in cultured supernatants from treated human 
neutrophils.  Culture supernatants were collected from human neutrophils treated with 
IgY/IgY(ΔFc) antibodies, mammalian IgG antibodies, PMA (positive control), LPS 
(positive contro), or untreated cells (negative control) 12, 24, and 72 hours after 
treatment.  Neutrophil elastase levels were quantified using a kit containing a non-
flourescent elastase substrate, which is selectively cleaved by elastase to generate a 
highly fluorescent compound R110 that can be read at an excitation wavelength of 
485nm and an emission wavelength of 525nm.  Each data point represents a mean ± 
standard deviation.  
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Discussion 
 In this study we present data to support the structural evidence that the use of 
avian IgY and IgY(ΔFc) antibodies in the mammalian system does not result in abnormal 
inflammatory responses.  The Fc portion of the mammalian antibody serves an important 
role in triggering many biological responses such as phagocytosis, endocytosis, antibody-
dependent cellular cytotoxicity, and release of inflammatory mediators, but inappropriate 
interaction of the Fc portion of antibodies with FcR can result in unnecessary 
inflammatory reactions.  These types of inflammatory reactions are sometimes seen when 
mammalian antibodies are used as passive antibody treatments.  HAMA and ADA 
responses can also form, resulting in an array of painful symptoms.  Structurally the Fc 
portion of avian IgY antibody is different than that of mammalian IgG antibody and is 
unable to interact with mammalian FcγR and activate immune pathways that can lead to 
unwanted inflammation [88,94].  Current and previous research has demonstrated that 
avian IgY/IgY(ΔFc) antibodies isolated from the eggs of vaccinated birds can be used 
effectively as a passive treatment against various antigens including bacteria and viruses.  
In our lab specifically, we have investigated and proven the effectiveness of goose 
IgY/IgY(ΔFc) antibodies in vivo as post-exposure treatment for hantavirus pulmonary 
syndrome caused by the Andes virus.  The purpose of this study was to determine the 
reactivity of avian IgY/IgY(ΔFc) antibodies and IgY(ΔFc) antibodies in the mammalian 
system to ensure its safety moving forward towards an increased use in humans.   
 In both the single and multiple injection studies animals receiving IgY/IgY(ΔFc) 
antibodies or IgY(ΔFc) antibodies did not show any abnormal pathology or inflammation 
compared to control animals injected with PBS or HRIG.  The only organ to show any 
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consistent abnormal pathology in both studies was the lungs.  Abnormalities observed in 
the lungs were not dependent on treatment.  Mice or rabbits in all treatment groups (IgY, 
PBS, or HRIG) developed hemorrhages or inflammation in the lung depending on how it 
was characterized in the study.  In the single injection study, hemorrhaging did get worse 
at later time points, but again the severity and frequency of occurrence was the same 
between the control and experimental groups.  The abnormal pathology in the lungs is 
therefore not dependent on treatment with IgY, PBS or HRIG specifically.   
 In this study we were able to show that IgY/IgY(ΔFc) antibody is safe for use in 
humans.  Goose IgY/IgY(ΔFc) antibodies were incubated in vitro with humans PBMCs 
and the production of select pro- and anti-inflammatory mediators was measured.  TNF-α 
and IL-1β are both proinflammatory cytokines produced by various immune cell types 
within the PBMC cell population.  Both of these cytokines are produced early in the 
immune response.  TNF-α is produced primarily by macrophages and promotes 
inflammation, activation of endothelial cells and allows extraversion of dendritic cells to 
the lymph node, further augmenting the immune response.  IL-1β is produced by 
dendritic cells and macrophages; it can help to activate other immune cells including T-
cells.  Our results indicate the PBMCs treated with goose IgY/IgY(ΔFc) antibodies 
produce only negligible amounts of IL-1β and no TNF-α compared to the positive control 
(Fig 10 and 11).  These results provide further evidence that IgY/IgY(ΔFc) antibody is 
safe for use within humans.  IL-10 is an anti-inflammatory cytokine able to inhibit 
activation and effector function of T-cells, monocytes, and macrophages.  Ultimately IL-
10 is responsible for terminating inflammatory responses, but also plays a role in 
regulating growth and differentiation of some immune cell populations [443].  When 
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cells were treated with IgY/IgY(ΔFc) antibodies there was no IL-10 detected in culture 
supernatants collected.  There was also no IL-10 produced by any other of the cell 
treatments.  It is unlikely that IgY/IgY(ΔFc) antibody is immunomodulatory and able to 
induce an anti-inflammatory environment.   
 The activity of NO in inflammation is less well understood than that of the 
cytokine previously described.  It is known that NO is released by activated macrophages 
and is known to regulate the activity, growth, and death of many immune and 
inflammatory cells including macrophages and T-lymphocytes [444].  Production of NO 
by PBMCs is indicative of immune cell activation and an ongoing inflammatory 
response.  There was no difference between the NO levels of PBMCs treated with 
mammalian IgG and those treated with IgY/IgY(ΔFc) antibodies.  Although there were 
low levels produced by cells treated with IgY/IgY(ΔFc) antibodies, the effects of NO are 
dependent on local concentration and levels produced by treated cells were low enough to 
not be of concern.   
 In order to look at the reactivity of IgY/IgY(ΔFc) antibodies with another 
population of innate immune cells, elastase release from activated neutrophils was 
measured.  Neutrophils are relatively short lived white blood cells that can function in 
several ways at the site of inflammation including phagocytosis, cytokine release, and 
degranulation [445].  Neutrophil elastase is an active enzyme stored within the granules 
of neutrophils until the cells are activated.  Upon activation neutrophil elastase can be 
excreted from the cell as a free protein or be associated with networks of extracellular 
traps (NETs) [446].  Neutrophil elastase is a serine proteinase that can attack a number of 
host proteins outside of the neutrophil and can have a damaging effect on host tissues if 
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release is triggered unintentionally [447].  Previous research seeking neutrophil elastase 
inhibitors alluded to the ability of mammalian IgG being able to actually induce NET 
formation [448].  It was therefore important that we test the ability of IgY/IgY(ΔFc) 
antibodies to activate neutrophils and lead to elastase release.  Treatment of neutrophils 
with IgY/IgY(ΔFc) anitbodies led to elastase release, but it took until 24 hours post-
treatment to reach levels similar to mammalian IgG (Fig 13).  The reason for what 
appears to be more activation of human neutrophils over immune cells present in the 
human PBMC population is unknown.  A better understanding of the direct interaction of 
IgY antibodies with mammalian cells is required.   
 This research demonstrates that IgY/IgY(ΔFc) antibodies are safe for use in the 
mammalian system.  The single and multiple injection studies along with the in vitro 
cytokine data clearly support the structural evidence that IgY/IgY(ΔFc) and IgY(ΔFc) 
have limited immunoreactivity within the mammalian system.  Based on these results, 
IgY continues to remain a viable option for use as passive antibody immunotherapeutics.   
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CHAPTER V 
DISCUSSION 
 In recent years there has been an increased interest in avian-derived antibodies as 
a unique source of passive therapeutics.  Avian antibodies have the potential to extend 
beyond current passive antibody therapeutic technology that primarily utilizes 
mammalian antibodies.  The majority of mammalian antibodies are of murine origin and 
come with the risk of high immunogenicity in humans.  IgY is the primary serum 
immunoglobulin of birds and is transferred to the egg yolk during embryo development; 
this results in the egg yolk having high IgY concentrations [21,44].  The egg yolk then 
becomes an easily accessible source of antigen- specific IgY antibodies.  Most past and 
presently researched avian antibody treatments are polyclonal in origin; in an attempt to 
move IgY antibody therapeutics in a new direction part of this current research focused 
on the development of a goose monoclonal IgY antibody that could be used to treat 
DENV-2 infections.  Currently, monoclonal antibody therapeutics are used to treat 
transplant rejection [449-451], cancer [452-458], and autoimmune disorders [459-464].  
Surprisingly, the use of these treatments for infectious diseases is limited [465].  The 
advantages of using avian monoclonal antibodies are three fold: the antibodies produced 
by the hybridoma are homogenous, the response generated is consistent, and the need to 
collect raw materials from SPF birds is eliminated.  In the present study, we were able to 
successfully complete the initial stages of hybridoma formation and mAb production, but 
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fusions did not last over time.  To the best of our knowledge this is the first 
demonstration of successful fusion between avian B-cells and mammalian myeloma cells.  
Previous research in the area of avian monoclonal antibody development has utilized 
chicken myeloma cell lines fused with immune chicken spleen cells [339,341,342].  
Despite being unable to develop stable long lasting hybridomas we were able to 
successfully show that the vaccinated geese did generate antigen- specific immune 
responses, including the production of antibodies, as indicated by the presence of antigen- 
specific antibodies in goose serum.   
 Polyclonal avian therapeutics have been developed utilizing chicken IgY 
antibodies against various antigenic targets, but the use of IgY antibodies from 
anseriformes birds has been limited to only a limited number of viral antigens [427,435].  
In our research we focused on ANDV and the development of a polyclonal goose IgY 
antibody treatment for HPS caused by ANDV.  It is well established that the humoral 
immune response is important for a favorable clinical outcome from HPS [350,422-424].  
Consistent with findings that virus- specific antibodies play an important role in patient 
recovery from HPS, when ANDV- specific goose IgY/IgY(ΔFc) antibodies were given to 
hamsters after challenge with a lethal dose of ANDV all of the hamsters survived.   
 The neutralizing titers of ANDV specific IgY/IgY(ΔFc) antibodies in the serum of 
vaccinated geese provided insight into the humoral response of geese.  Most interestingly, 
neutralizing titers were maintained during the year in between vaccinations.  It is 
unknown if this type of response is typical of all birds and to all antigens.  After booster 
vaccination neutralizing titers were nearly ten fold higher.  Along with the increase in 
neutralizing titers there was also an increase in reactivity of IgY/IgY(ΔFc) antibodies 
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isolated from eggs of booster vaccinated geese with epitopes on the surface of both 
glycoproteins.  The increase in titers and reactivity with epitopes suggests that collecting 
antibodies after a booster vaccination series may provide an improved passive IgY 
antibody treatment with better neutralizing capabilities.  
 For the epitope mapping experiments, IgY/IgY(ΔFc) antibodies from the egg 
yolks of geese, were separated into the full length (IgY) antibody and alternatively 
spliced (IgY(ΔFc)) antibody isotypes, after the initial vaccination series.  In general, the 
two isotypes reacted with same epitopes on the virus glycoproteins, but there are potential 
advantages being able to use only the IgY(ΔFc) isotype.  In the avian system IgY(ΔFc) is 
unable fix complement or sensitize the tissues to allergic reactions, functions that are 
thought to require the Fc portion of the IgY isotype antibody [49].  Even without the 
ability to carry out Fc-mediated functions IgY(ΔFc) antibody has still retained its ability 
to neutralize viruses within the avian system [44].  Because it is lacking the two constant 
domains compared to the full length isotype and one constant domain compared to 
mammalian IgG, reactivity within the mammalian system is likely to be limited.  Results 
from our in vivo multiple injection study indicated there was no abnormal pathology in 
rabbits injected with IgY(ΔFc).  Future studies looking directly at the reactivity of the 
IgY(ΔFc) isotype with human PBMCs may be useful to gain more information on the 
inflammatory potential of this specific isotype of IgY.   
 Regardless of the type of avian antibody treatment being used and the target, the 
safety of the treatment for use in the human body is important.  In our study we were able 
to show through in vivo single and multiple injection studies that treatment of animals 
with IgY/IgY(ΔFc) or IgY(ΔFc) antibodies did not result in any abnormal pathology or 
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signs of inflammation compared to control animals.  Also, IgY/IgY(ΔFc) antibodies did 
not induce inflammatory cytokine production by human PBMCs, another indication of 
the safety of IgY within the mammalian system.  The positive safety results along with 
the success of the ANDV- specific IgY/IgY(ΔFc) antibodies as a post-exposure treatment 
for HPS caused by ANDV continues to advance the field of avian IgY antibody 
treatments towards more human trials.   
 An important next step in the area of avian antibody treatments is to identify the 
receptor on cells in the mammalian system, specifically humans, with which IgY and 
IgY(ΔFc) antibodies are able to interact with.  Knowing this information would be 
helpful in determining what mechanisms IgY and IgY(ΔFc) antibodies use for clearance 
of antigens and to generate protection.  Also, information about the receptor would be 
useful to better understand and test for the potential reactivity of the antibody within 
humans, and how potentially the antibody could be modified and still be functional.   
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